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"The Doctors, who ought to know 
Assure us that this might be so....
Oh! Let us never, never doubt 
What nobody is sure about."
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ABSTRACT
The effect of large doses of vitamin C (3g ascorbic acid daily) 
on the ascorbic acid status and urinary excretion of hydroxyproline 
in 52 early breast cancer patients compared to 10 benign f patients has 
been investigated.
The leucocyte ascorbic acid levels of the early breast cancer patients
did not increase to those levels found in the patients with benign
disease. This may be due to reduced absorption of the vitamin, the effects
of radiotherapy and drugs, or, as has been discussed, these patients may
have an increased requirement for ascorbic acid due to the presence of
residual neoplastic cells. It is possible that these^patients could have
been excreting the vitamin at a greater rate. Further kinetic studies,
involving the administration of a 3g loading dose of the vitamin, were
carried out. The excretory profiles of the 3 groups studied (early breast
[individuals
cancer, benign and normal A  showed dramatic differences, suggesting 
that the restriction in the rise in leucocyte ascorbic acid concentration 
following supplementation could be a reflection of a widespread change in 
the general metabolism and utilisation of the vitamin in early malignant 
disease.
During the course of study (March 1978 - October 1980), 5 of the early 
breast cancer patients showed clinical signs of skeletal involvement 
which were confirmed by positive bone scans. The metabolic profiles of 
these patients have been examined and the relationships between various 
plasma and urinary parameters are discussed in the light of the 
chronological development of osseous deposits. Additional longitudinal 
studies were carried out in advanced breast cancer patients with skeletal 
metastases. In particular, one patient (age 36 years) was closely observed 
for a period of 11 months. Sequential plasma ascorbic acid, calcium 
and alkaline phosphatase were carried out at monthly intervals to within
8 weeks of her death. These results are conflicting. However, the
! advantageou s
results do indicate that it may he ■-••Ho use ascorbic acid
supplementation in patients with breast cancer as a standard supportive 
measure.
Opportunity was taken to study the tryptophan metabolism in 51 
early breast cancer patients compared to 14 patients with benign breast 
disease. The plasma total tryptophan concentrations were consistently 
lower in the cancer group, whilst N'-methylnicotinamide excretion was
higher. The mean plasma total tryptophan level of the cancerous group
I through the s tudy y 
increased with time^decreased with age and seemed to be unaffected by
the presence of disseminated disease. These trends were not reflected in
any of the urinary metabolites studied. The aetiology of these tryptophan
disorders has been discussed in the light of the dramatic differences|observed! 
[between1
^pre and post - menopausal tryptophan status observed, which may be 
indicative of the possible hormonal control mechanisms operating in this 
pathway.
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CHAPTER ONE 
1. INTRODUCTION
1.1 Breast Cancer
1.1.1 Incidence and Epidemiology
Breast cancer is the most common cause of death from neoplastic 
disease in women of the Western World. On presently available knowledge 
1 in every l*f women is destined to develop breast cancer and about 3 new 
cases of breast cancer are being diagnosed every 15 minutes in the United 
States (Holleb, 1977)• In England and Wales the rate of incidence per 
100,000 women in 1972 was 76.8, 17* 3» 15*6, 22.4 for cancer of the breast, 
stomach, ovary and lung respectively (HMS0 cancer statistics, 1972-1973)* 
The rate of incidence for the S.W. Metropolitan area, including St. Luke's 
Hospital Guildford, quoted in 1971, is 82.7 which is similar to the 
national average figure of 72.4.
The incidence of breast cancer varies throughout the world. It is 5
to 6 times higher in N. America and Northern Europe than in most areas of
Africa and Asia. Southern Europe and S. America have intermediate rates
(Doll et al., 1966). DeWaard (1969) has also identified striking changes
- incidence}
in age incidence patterns. Where rates are high the A  increases ^towards 
menopause ' then levels off and after the menopause actually declines. 
Areas of intermediate risk show intermediate age patterns (fig l) (Levin 
and Thomas, 1977)* This is true of other female cancers (Anthony, 1976). 
Further studies have shown that migrants from low to high risk countries 
develop breast cancer at rates intermediate between those of natives of 
countries of origin and adoption (Haenszel and Kurihara, 1968). Also the 
rates in succeeding generations tend to approximate those of natives of 
the country of adoption with the passage of time (Buell, 1973)* Such 
evidence suggests that environmental factors rather than those of genetic 
origin play a major role in the genesis of breast cancer. The major 
factors known or suspected to increase or decrease the risk of developing 
breast cancer in women are summarised in Table 1 (Levin and Thomas, 1977)* 
Several reviews of the risk factors associated with breast cancer have been
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Table 1. Major Risk Factors for Breast Cancer in Women
FACTOR 
Ge ographic/Ethnic
Increasing age 
Age at first birth
Parity
Age at menarche
Age of natural menopause
Oophorectomy
Nutritional
Ionising radiation
Previous cancer
Familial
Prior benign breast 
disease
INCREASED RISK 
N. American,
W. European.
old
after age 30
nullparity 
before age 13
after age 50
none
obesity
ionising radiation
breast, endometrium, 
colon, rectum, 
salivary gland, 
ovary.
family history of 
breast cancer
fibro-cystic breast 
disease (especially 
with ductal atypic)
DECREASED RISK 
Japanese, Taiwanese,
S. African blacks, 
Nigerian blacks, 
Indians.
young
before age 20
parous before age 20 
after age 16
before age 45
before age 45
none
none
cervix
none
none
published (Wynder et al., I96O; Macmahon ^ t al. ,1973; Hankin and Rawlings, 
1978; Habs and Schmahl, 1980) and relationships of disease with age, 
socioeconomic status, family history, lactation, previous benign disease,4, 
ages of menarche and menopause, reproductive experience, obesity and 
geographical residence have been reported. Epidemiological data has 
indicated that diet may be an important environmental variable in the 
aetiology of breast cancer. Most of the reports on the relationships of 
diet with breast cancer in human populations have been limited to studies 
of varying nutrient intakes according to geographical location, and these 
will be discussed in the light of experimental findings.
1.1.1.1 Energy Intake
Epidemiological studies have shown that obesity is correlated with 
breast cancer in humans (Wynder and Mabuchi, 1972). Case control studies 
have also shown obesity to be more common in breast cancer patients than in 
controls (DeWaard, 1969; Basu and Williams, 1975)* Carroll and Khor (1975) 
plotted mortality from breast cancer in different countries-against 
energy intake for these countries, published by the Food and Agriculture 
Organisation (1971). They found that the age adjusted death rates showed 
a strong positive correlation with caloric intake (r * +O.796) but this 
was not as strong as with fat intake. DeWaard (1969) suggested that the 
main environmental factor accounting for the geographical distribution 
of breast cancer is ovemutrition. He assumed two aetiological types of 
breast cancer, one mainly restricted to reproductive life in which some 
hormonal imbalance favourable to tumourgenesis is present, the other 
in which post-menopausal adrenocortical abnormalities such as oestrogen 
production brought about by increased nutritional status could play a 
causal role. Lipsett (1975) studied the effects of obesity on steroid 
metabolism in women with breast cancer. He concluded that obesity may 
increase plasma oestrogen by producing a higher rate of secretion of the 
oestrogen precursor androstenedione and an increased rate of conversion
of this precursor to oestrogen. It is known that environmental factors 
by affecting nutritional status have an effect upon hormonal metabolism 
in experimental animals (Glass and Swerdloff, 1980) and DeWaard (1975) 
later modified his hypothesis indicating that body size or body mass 
rather than overweight was the risk factor involved. Experimental 
evidence has been found to support this. Both underfeeding in which the 
intake of all nutrients is restricted and energy deprivation per se in 
which only carbohydrate or carbohydrate and fat are reduced has been shown 
to inhibit mammary tumour formation in mice (Tannenbaum and Silverstone, 
1957)• Similar results have been obtained with induced mammary tumours in 
rats (Moore and Tittle, 1973)* Waxier and collegues (1953) demonstrated 
that mice made obese developed spontaneous mammary carcinomas at a faster 
rate than controls. Waxier (1954) provided evidence which suggested that 
rather severe energy restriction is needed to produce an inhibitory 
effect on tumour formation.
1.1.1.2 Protein Intake
Carroll and Khor (1975) found a strong positive correlation between 
animal protein intake and breast cancer mortality for different countries, 
but this was diminished when the total protein intake was considered.
Drasar and Irving (1973) correlated an estimate of the daily, per capita 
food availability in 37 countries with incidence rates of carcinoma of the 
breast. A notable association was found between breast cancer and the 
consumption of fat and animal protein. This would seem to be understandable 
since these two dietary components are often complementary. Data published 
by White et al. (1947) indicated that the induction of leukaemia in strain 
DBA mice by painting with methylcholanthrene could be markedly influenced 
by the restriction of cystine in the diet, which raised the question of 
protein quality versus intake per se as the aetiological factor. The 
experimental evidence available does not provide a clear picture of the 
influence of the type of protein in the diet on tumour formation; although
it does seem that severe protein restriction may reduce the incidence 
of mammary tumours in experimental animals.
1.1.1.3 Dietary Fat
Lea (1966) found that in 23 countries, a high correlation existed
between the per capita consumption of fat and death rate of breast cancer
in these countries, cholesterol was suspected as the responsible agent for
this association. However, the results of 5 clinical trials carried out in
Los Angeles showed that cholesterol-lowering diets did not influence
cancer risk in the male veterans studied (Pearce and Dayton, 1971; Ederer
et al., 1971). A study of regional variation in mortality rates in the
British Isles by Stocks (1970) demonstrated that breast cancer rates were
positively associated with dietary intake per person of butter, cheese,
milk and green vegetables. Moreover, total fat intake has shown a greater
correlation with the mortality from breast cancer than that of animal or
vegetable fat (Carroll and Khor, 1975)• Recently, breast cancer incidence
and mortality rates in different countries were discovered to be correlated
with total fat and animal protein consumption after controlling for the 3
anthropometric variables of height, weight and age of menarche (Gray et al.
1979). Similar dependence of breast cancer mortality upon fat intake has
been demonstrated in 20 different countries and this lead the author to
suggest a causal association between the disease and this nutrient. The
plasma of postmenopausal women with breast cancer contains higher
concentrations of total lipids, phospholipids, cholesterol and lipase
activity than that of age matched women with cancer at other sites; the
latter group had similar mean values to those of a group of female
hospital patients of similar age who did not have cancer (Basu and Williams
>serum
1975). The high concentrations of^cholesterol recorded in patients with 
advanced breast cancer do not seem to be due to the biological state of 
the tumour, since similar high values were found in patients with early 
breast cancer (Smethurst et al., 1975)•
Animal studies have shown that diets rich in fat enhance the development 
of dimethylbenzanthracene (DMBA) induced breast cancer in rats (Carroll 
and Khor, 1970) and similar diets enhanced the development of breast 
neoplasia in mice (Szepsenwol, 1964). However, these studies utilised 
artificial systems (and the mouse model is known to be virus mediated) and 
therefore results must be interpreted with appropriate caution. Hill et al., 
(l971a) postulated that the effects of fat in the diet were mediated by gut 
bacteria in that the composition of gut flora is known to be dependant on 
diet; and in particular the amount of dietary fat. Secondly, the amount of 
dietary fat also determines the quantity of biliary steroids in the colon 
which may be transformed by the gut flora to produce carcinogens. Thus, 
individuals ingesting high fat diets have a high faecal flora and large 
amounts of metabolically inactive anaerobic bacteria, and excrete high 
concentrations of neutral and acid steroids, which may be transformed to 
carcinogenic substances. Previously it was established that people living 
on high fat diets tend to have faecal flora containing a high proportion 
of the very metabolically active strictly anaerobic bacteria (Hill et al., 
1971b), furthermore the subjects excreted greater concentrations of acid 
and neutral steroids (Hill, 1971). The possibility of production of 
oestradiol, oestrone and 17-methoxy-oestradiol from androstenedione by 
intestinal bacteria has been investigated (Goddard and Hill, 1972).
Since high fat diets appear to exert an effect on tumourgenesis when 
administered to experimental animals after the cocarcinogenic agent, 
dietary fat may be considered to exert a promoting action on skin and 
mammary tumours (Carroll and Khor, 1975). Both Lavik and Baumann (1943) and 
Tannenbaum (1942) considered this possibility, which they referred to as 
a systemic cocarcinogenic action exerted during the developmental stage of 
tumourgenesis. Chan and Cohen (1975) felt that mammary tumour cell 
proliferation was promoted by a raised prolactin/oestrogen ratio caused by 
increased prolactin levels following chronic high fat intakes.
In conclusion, the reports on correlations in human studies are 
dependant upon the accuracy of either incidence or mortality data cited 
and estimated food intake or availability figures. The reliability of such 
data must be questioned and although mortality figures are more complete 
they are subject to inaccuracies in diagnosis and reporting.
The composite nature of tumourgenesis has been well argued (Bailar,
1979) and in the epidemiology of a disease, which is multifactorial to 
such an extent as breast cancer is believed to be, attention should be 
paid even to "weak" factors and an attempt should be made to assign a 
place to them in an aetiologic system which is biologically sound (DeWaard
1969).
1.1.2 Hormones
It is evident from the foregoing discussion that many postulated
mechanisms of carcinogenesis or promotion are hormonally mediated.
Hormonal effects may be indirectly associated with observations of the
protective effect of later menarche (Staszewski, 1971; Juret et al., 1976)
pregnancy, lactation (Lane-Claypon, 1926; Wainwright, 1931) and moreover
the greatly differing incident rates pre and post menopausal (Lilienfeld
%
and Johnson, 1955). Many studies have been carried out exarpng the 
hormonal status of women with varying degrees of risk of breast cancer 
(Bulbrook et al., 19765 Wang et al., 1979) But the association between the 
two remains unclear. A detailed examination of the evidence available for 
the role of various hormones in the aetiology of breast cancer is beyond 
the scope of this thesis. Hayward (1970) has reviewed the literature on 
the subject, and sums up the state of our present knowlege as followss-
"There is now evidence that the sex linkage in breast cancer can be 
accounted for by the differences in the hormonal environment between men 
and women. The incidence in men can be increased probably to a rate 
similar to that in the female by the administration of oestrogens or by
feminising conditions; also there is evidence that men with breast cancer 
metabolise oestrogen abnormally. The prescription of oestrogen to women 
does not have the same effect* moreover there is only circumstantial 
evidence that endogenous hyper-oestrogenism may be associated with the 
high incidence of breast cancer - that is only in postmenopausal women.
Reports of alterations in oestrogen excretion in women with the established 
disease have been conflicting. On the other hand, there are now observations 
showing that many women with breast cancer have abnormalities in androgen 
and corticoid excretion. One investigation has indicated that these 
abnormalities may precede the onset of disease.
Thus, although there is no direct evidence that androgens, oestrogens 
or indeed any known hormones are carcinogenic in men or women, certain 
abnormalities in the hormone milieu, probably acting with other unknown agents, 
may condition breast tissu# to neoplasia. These abnormalities are highly 
complex and may take different forms; that is to say may engender similar 
neoplastic changes. Providing the hormonal environment is favourable for 
neoplasia, local factors are likely to determine when the cancer appears 
and its siting within the breast."
Similarly, the controversy over the role of prolactin has not been 
resolved at the present time. Many studies have shown that prolactin 
levels in patients susceptible to breast cancer and their relatives are 
often normal. However some recent work, especially that of Morgan and 
assdciates (1975) points to the fact that some tumours axe dependant on 
high levels of prolactin, while some others axe dependant on low levels. If 
this is true the measurement of mean prolactin levels would have no great 
significance.
The second area of hormone involvement is that relating to the prognosis 
of the disease. Lett (19Q5) described his results of castration in 99 
women with the advanced disease. 35 of them (J&fo) were improved, and all 
of these women were below 50 years of age. Lewison (1965) reviewed the
extensive literature on this subject and found that about one third of 
premenopausal women with advanced disease benefitted from surgical or 
radio-therapeutic castration. Work has been carried out to attempt to 
correlate the oestrogen receptor orosstrophilin content of an exeised 
specimen of tumour with objective response to endocrine therapy (Jensen 
et al., 1977).
1.1.3 Classification
1.1.3*1 Pathology
The great diversity of pathologic picture has given rise to many 
classifications and histologic terms. However it is possible to distinguish 
two main groups of tumours, one in which diffuse infiltration is the main 
biological characteristic, the other more localised (carcinoma in situ)! and 
therefore of different clinical significance. Unfortunately, the former is 
more common. This is the essence of classification. Table 2 shows the 
principle components of the classification system.
1.1.3.2 Grading of Tumours
Breast carcinoma is also graded with regard to the extent to which the 
cancer cells have aquired the ability to resist homeostatic mechanisms of 
the host. Grading techniques now being used are based on a subjective 
evaluation of the cancer cell population and the extent to which normal 
histologic patterns are reproduced. Generally the grades are distinguished 
as follows
Grade X - Mature well differentiated
Grade II - Moderately mature - partly differentiated
Grade III - Immature undifferentiated
Grade IV - Unclassified
1.1.3*3 Lymphocytic Response
In some cases the pathological report also includes an appraisal of 
host resistance. Infiltration of the primary tumour by lymphocytes, the
Table 2. The Principle Components of Breast Cancer Types.
(after Foote and Stewart,19^ 6; Boyd, 1967 and Louis, 1978)
I Paget’s Disease of the Nipple
II Carcinomas of Mammary Ducts
a. Noninfiltrating tumours -
(Carcinoma in situ)
b. Infiltrating tumours
III Carcinomas of Mammary Lobules
a. Noninfiltrating
b. Infiltrating
Solid intraduct carcinoma 
Comedo carcinoma 
Cribiform carcinoma 
Papillary carcinoma
Adenocarcinoma (schirrous carcinoma) 
Medullary carcinoma 
Mucoid carcinoma 
Squamous cell carcinoma
IV Relatively Rare Carcinomas
presence of plasma cells at the advancing margin of the growth and 
reactive hyperplasia of the regional lymph nodes are all associated with a 
prognosis which is relatively favourable (Delarue, 196 )^. In this study, 
this observation was noted by the pathologist as a brisk lymphocytic 
response. A minimal lymphocytic response denoted little host resistance.
1.1.3.^ Clinical Staging of Breast Cancer
Breast cancer spreads radially, infiltrating through tissue spaces and 
invading adjacent lymphatic and blood vessels. Part of the spread may be 
by lymphatic permeation as originally described by Handley (1922), but the 
important method is by lymphatic embolism. There are two main pools into 
which drain the lymphatics of the breast, the axillary nodes, draining the 
upper outer quadrant and the chain of nodes along the internal mammary 
artery draining the inner part of the breast (Handley and Thackray, 19^7).
As the most common location of the tumour is the upper outer quadrant, it is 
inevitable that the axillary nodes should be involved early. These nodes 
show microscopic involvement in up to 6($ of cases when the patient is 
first seen (MacDonald, 1951). Thus in a series of cases in which axillary 
lymph glands were not palpable, serial sections revealed metastases in the 
nodes of (Saphir and Amromin, 19**8).
The extent of the disease is described, on the basis of clinical 
findings, using the TNM classification. This was devised by the Union 
Internationale Contre le Cancer (UICC, 1968), The initial TNM classification 
of any one patient will obviously change with surgery, radiotherapy or as 
the disease progresses. The letter T refers to the clinical extension 
(size) of the primary tumour, N to the clinical appearance of adenopathy 
(node involvement) and M to the existence or not of distant metastases.
Table 3 shows the various subdivisions of the classification (Denoix, 1970).
Table 3* The Subdivisions of the TNM Staging System 
(Denoix, 1970)
T Primary Tumour
Tq No evidence of primary tumour 
T^ Tumour ^  2cm in greatest dimension
Tg 2cm < Tumour ^  5cm
T^ 5cm ^ Tumour < 10cm
Tumour > 10cm in greatest dimension
N Regional Lymph Nodes
Nq No palpable homolateral axillary nodes
Moveable homolateral axillary nodes
N2 Homolateral axillary nodes fixed to one another or
to other structures
N~ Homolateral supra - or infra - clavicular nodes, 
moveable or fixed, br^ oed^ iaia^
M Distant Metastases
Mq No evidence of distant metastases
M1 Distant metastases present
M^a Skin involvement wide of breast
M-,, Involvement of contra lateral nodes or contra
lateral breast
M, Clinical or radiological evidence of metastases
to lungs, pleural cavity, skeleton, liver etc.
l.l.Jf Detection and Treatment
The accuracy of diagnostic techniques, to a certain degree, determines 
the prognosis of the disease. McDivitt and Ellis (1971) established an 
inverse relationship between time of diagnosis after onset of disease 
and length of survival. The breast clinic at St. Luke's Hospital,
Guildford, primarily use clinical examination and mammography techniques.
The latter involves soft tissue X ray methodology. Further diagnostic 
facilities available at other hospitals include xeroradiography, 
thermography and mammometry, which have been fully discussed by Gershon- 
Gohen and Hermel (1969), Gallagher (1975) and Henderson and Canellos 
(1980).
Recently, St. Luke's Hospital, Guildford has instigated a regional 
screening programme. However, there has been some controversy over the 
use of mammography for examining large populations due to the theoretical 
danger of radiation-induced neoplasia (Bailar,1973)• It has been shown 
that if two or more diagnostic techniques are employed the rate of 
discovery of smaller cancers is increased (Furnival et al., 1970 j Hicks 
et al., 1979). For example 1,768 women were screened over a period of 
one year using thermography and mammography. Breast cancer was detected in 
15 patients, none of whom were aware of any abnormality, in spite of the 
fact that 13 of the tumours were clinically palpable (Davey et al., 1970). 
Similar emphasis is put on the initiation of early treatment. The clinician 
is able to use any combination of surgery, radiotherapy, chemotherapy, 
hormone therapy and immunotherapy for any one patient. The individual 
treatment regimen of a cancer patient is determined by such factors as 
age, hormonal status, extent of disease, nutritional status, etc.
All the early breast cancer patients in this study had undergone 
surgery, which may have involved a simple biopsy or mastectomy. Three 
types of mastectomy can be carried out.
a) Radical mastectomy involves the removal of the breast plus 
pectoral muscles and ipsilateral axillary lymph nodes.
b) Patey mastectomy differs from above in that after surgery 
the pectoral muscles remain intact.
c) Simple mastectomy involves the removal of the bulk of the 
breast tissue, and a local axillary node dissection may be 
carried out.
Radiotherapy may be used as a primary treatment in patients who are 
unsuitable for operation or as palliative therapy for the relief of local 
symptoms. As a general principle, the sensitivity of a tissue to radiation 
goes hand in hand with the rate of cell turnover in that tissue. Thus, 
rapidly growing, poorly differentiated tumours are generally more 
radiosensitive than slowly growing well differentiated tumours. The 
advantages of this type of treatment lie in its speed of administration 
and relative lack of side effects.
Chemotherapy involves the oral or parenteral administration of cytotoxic 
drugs, which derange the mitotic cycle and consequently cause cellular 
death. Obviously the dosage must be calculated to cause maximum lethality 
to the cancer cells without causing exessive damage to peripheral cells. 
Antitumour drugs can be classified according to the specificity of their 
action with regard to the cell cycle (fig 2).
St. Luke's Hospital, Guildford favour the use of a ,32 day FOME" 
composite chemotherapy regimen for the treatment of breast cancer patients. 
This quadruple chemotherapy is schematically represented in fig 3*
Vincristine and endoxana have similar toxic side effects such as 
bone marrow depression, leading to a fall in white blood cell counts, and
Fig. 2 THE MAIN SITES OF ACTION OF ANTITUFiOUR DRUGS IN RELATION 
TO THE CELL CYCLE (AFTER LOUIS, 1978)
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later, red blood cells will also be affected. Nausea and vomiting are 
frequent complications. These drugs frequently damage the mucosal surfaces 
of the small and large intestine, leading to diarrhoea and malabsorption. 
The effectiveness of methotrexate and 5-fluorouracil is due to their 
interference with the synthesis of nucleic acids. Methotrexate, a 
derivative of folic acid, acts principally by the competitive inhibition 
of the enzyme dihydrofolate reductase, thus preventing the reduction of 
dihydrofolate to tetrahydrofolate, a necessary step in the process of DNA 
synthesis and cellular replication. Side effects occur as a result of 
cytotoxic activity on rapidly reproducing normal cells of the haemopoietic 
system, gastrointestinal tract and sometimes skin. Consequently, common 
adverse reactions are bone marrow depression, leucopenia, nausea, vomiting, 
diarrhoea and ulcerative stomatitis. The toxicity is slightly reduced by 
giving folic acid intravenously or intramuscularly, but the clinical 
effectiveness is reduced even when folic acid is given some hours after 
methotrexate. 5“fluorouracil is a fluorinated pyrimidine, inhibiting cell 
division by interfering with the synthesis of DNA and to a lesser extent 
of RNA. In addition to those side effects previously listed it appears 
that this drug may depress circulating effective thiamin as a result of a 
reduction in the phosphorylation of thiamin to its active coenzyme, 
thiamin pyrophosphate (Basu et al 197^ a). These cumulative effects may 
leave patients with a prolonged nutritional insufficiency (Ohnuma and 
Holland, 1977). Since the epithelial cells of the small intestine have a 
relatively rapid turnover, it is to be expected that many of these drugs 
will adversely affect intestinal functions to a degree depending on the 
drug dosage, the duration of treatment, the rates of metabolism and 
individual susceptibility (Ohnuma and Holland, 1977)* Shils (1979) has 
summarised the effects of various agents on the alimentary tract, which 
may cause prolonged periods of anorexia and nausea with resulting impaired 
food intake. Complications in taste and salivary secretion have been
documented in patients receiving radiotherapy to the head and neck area 
(MacCarthy-Leventhal, 1959) and radiation damage to the small and large 
bowel (Donaldson, 1977) creates a multitude of nutritional problems. In 
addition to this, it is known that active neoplastic disease itself is 
often accompanied by marked anorexia and wasting ("cancer cachexia") which 
is not directly attributable to obvious intestinal obstruction, sepsis, 
endocrine disorder or other anatomic lesions. It is manifested most 
commonly and noticeably in patients with cancer in one or more areas of the 
alimentary tract including liver and pancreas (Shils, 1979) and in those 
with widely disseminated disease. Cachexia and weight loss have been the 
subject of many publications (Theologides, 197^; DeWys, 1977? Costa,11977» 
Morrison, 1978) yet its cause remains uncertain. In addition to these 
general effects, various neoplasms may have a number of more localised 
effects leading to nutritional problems (Shils, 1979)* By far the most 
common causes of malnutrition in this general catagory are interferences 
with food intake as a result of partial or complete obstruction of some 
portion of the gastrointestinal tract. Relief of obstruction by surgical 
or other treatment is necessary. Nutritional support by intravenous 
alimentation or tube feeding into a site distal to the obstruction may be 
very useful in sustaining such patients until normal oral feeding can be 
reinstituted following effective surgical or other therapy. Holland et al, 
(1977) have identified psychological components which may cause transient 
anorexia at various stages in the disease. Anorexia may be prevalent at 
the time of the diagnosis of the primary disease or a recurrence, where 
it is an emotional response occuring in the context of general anxiety 
and depressed mood. Presence of pain; lack of sense of well-being, anxiety 
for the future and hospitalisation itself diminish the possibility for 
"enjoying a good meal". It could be anticipated that these are the most 
important factors in the cachexia of breast cancer.
It has been postulated that adequate nutrition may be important for
the success of whatever form of therapy is administered (Bertino, 1979).
For example, asparaginase is an enzyme that induces impairment of protein 
synthesis and has also been used to stop methotrexate action, since 
methotrexate requires optimum protein and RNA synthesis for maximum kill 
(Capizzi et al., 1977). Since asparagine deprivation selectively kills 
lymphoblasts this enzyme does not rescue lymphoblasts, which continue to be 
killed by asparaginase. This combination has resulted in some excellent 
results in the treatment of patients with acute lymphoblastic leukaemia. 
Nutritional supplementation may also be used to enhance the efficiency of 
an antimetabolite by manipulation of normally operative metabolic controls. 
In the presence of amino acid or folate deficiency the antitumour activity 
of antimetabolites such as methotrexate and 5~f’luorouracil is limited and 
optimised in patients with a good nutritional status (Copeland et al.,
1977) « Similar potentiation of immimotherapeutic methods has been 
suggested since Copeland et al. (I976) fbund that delayed hyper- 
Asinsitiyity1factions 
restored by proper nutritional repletion.
1.1.5 Survival
There are many conflicting reports on the remission rate that can be 
expected following various treatments. Principally, this is because there 
has been no measure of agreement between various workers and centres on 
the criteria of a successful response. Indeed in some reports these criteria 
have not even been mentioned. Nissen-Meyer (1965) in his discussion on 
ablative endocrine therapy, listed 15 series including a total of 2,221 
patients, in which the remission rate varied between 15.2$ and 5<$. Such 
a variation could not be the result of different techniques of castration, 
nor of differences in patient material available to each investigator. More 
likely, it is because each assessment was related to different criteria 
of success. Some physicians were satisfied that a response had occurred 
when the growth of a few lesions was retarded and there was relief from
pain. Others required evidence that all lesions had diminished in size 
and that no lesions had occurred, albeit for a very short time. Still 
others imposed a time limit on success and refused to accept a period of 
remission of less than 6 months.
Using UICG recommended response criteria (Hayward et al., 1977),
Priestman et al. (1978) found that only 17 out of 92 patients with advanced 
breast disease treated with cytotoxic drugs or endocrine therapy showed 
complete responses. Research at the Royal Marsdeh Hospital, Sutton indicated 
that the use of multiple drug chemotherapy had not improved the overall 
survival of patients with primary breast cancer (Powles et al., I98O). O'Lang- 
lands et al. (1979) compared the mortality-of 3,878 ,cases of breast■cancer 
with that in an equivalent normal population using Scottish national age- 
specific death rates and concluded that only patients who had undergone 
the menopause before presentation and who were disease free 15 years after 
primary treatment may prove to have been cured by conventional techniques 
such as simple mastectomy and post operative radiotherapy. The results of 
treatment of early breast cancer had not significantly improved in the 20 
years prior to 1966 (Lewison et al., 1966) and although there are various 
trials in progress aimed at evaluating the many treatment modalities for 
this disease there is a growing body of opinion that no particular permutation 
of the alternative operations with or without radiotherapy is likely to 
make a great impact on mortality rates (Fisher, 1970)•
1.2 Metabolic Changes
Various investigators have suggested that cancer per se, apart from 
depressed food intake, alters energy metabolism so that requirements are 
increased beyond those of normal individuals of otherwise similar status 
(Copeland and Dudrick, 1975). Young (1977) has reviewed 8 reports published 
between 1922 and 197^ on the basal metabolic rate of cancer patients. The 
results were variable, the cases relatively few and the available information 
limited; however, the majority indicated a tendency toward elevation
especially in patients with Hodgkin's disease and leukaemia. In a more 
recent study, energy expenditure and resting metabolic rates were found 
to be significantly greater in the cancer patient compared to controls.
The energy intake was not significantly different in these 2 groups 
(Wilmore, 1977) • Wamold et al. (1978) found an increased resting metabolic 
rate accompanied by raised energy expenditure in 10 cancer patients with 
various types of malignant tumour. Recently, however, Burke and Kark (1980) 
evaluated an alteration in the relationship between decreased food intake 
and change in body composition in 48 patients with gastro-intestinal 
cancer compared with 27 with benign gastro-intestinal disease. This did not 
appear to be due to differences in resting metabolic rate or the extent 
and pattern of dietary change. It is possible that an increase of energy 
requirement mediated by increased production of corticosteroids and 
catecholamines following fever, surgery and other causes of stress could 
result in increased protein catabolism and increased gluconeogenesis 
(Milmxieil 1977? Young, 1977). In addition, it has been proposed that the 
increased rate of resynthesis of glucose from lactate (Cori cycle) produced 
by the tumour results in a significant energy drain on host tissues. Cori 
cycle activity has been measured in a heterogenous group of patients with 
metastatic carcinoma and found to be increased in those with progressive 
weight loss (Holroyde et al.*' 1975)* Finally, it has been found that the 
disappearance rate of intravenous glucose is significantly lower in 
cachectic cancer patients as compared to non-cachectic cancer patients and 
tumour-free controls and that the former did not respond normally to 
glucagon; these observations could be due to impaired insulin release and 
indeed this has been suggested by Jasani et al. (1978).
Abnormal circulating levels of thiamin (Basu et al., 1974a), calcium 
(Swyer et al., 1950), alkaline phosphatase (Woodard, 1953) and ascorbic acid 
(Krasner and Dymock, 1974) have been reported in breast cancer patients.
In the same set of patients elevated urinary levels of hydroxyproline
(Cuschieri and Felgate, 1972) and certain tryptophan metabolites (Rose, 1967 a) 
have been demonstrated.
1.2.1 Calcium Metabolism
The first observation of hypercalcaemia known in malignant disease was 
probably made by Virchow in I885 and has been recognised as a common 
complication of many cancers (Warwick et al., 1961). The most frequent cause of 
hypercalcaemia is metastatic invasion of the bone (Gutman et al., 1936) in 
which the elevated circulating calcium is a simple expression of bone 
destruction, the mineral is liberated into the blood stream at a faster rate 
than it can be excreted through the kidney. This hypercalcaemia followed 
by renal breakdown are the final clinical features of osteolytic bone 
destruction actively preceded by hypercalciuria and hyperphosphaturia 
(Laszlo et al., 1952).The negative mineral balances which characterise 
osteolytic bone destruction are further exacerbated by reduced calcium 
absorption observed in these patients (Coombes et al., 1976). However, 
advanced malignancy is not necessarily a steady progressive disease but 
may proceed in waves of osteolytic activity followed by calcium retention 
caused by osteoblastic metastases (Laszlo et al., 1952).
The skeleton is screened for metastases using isotopes. Metastases 
evoke an osteoid reaction in the invaded bone and this immature osteoid 
tissue has an increased activity for bone seeking isotopes (Galasko, 1971) • 
Breast carcinoma has a predilection to metastasis© to the skeleton (Holland, 
1973). When a careful autopsy had been carried out, skeletal lesions were 
found in 85 per cent of women dying from this particular disease (Jaffe*, 1958). 
Numerous studies have demonstrated that bone scintigraphy with newer 
technetium Tc 99m-labelled phosphonates is the most sensitive test for 
detection of bone metastases, and that it is often positive prior to 
radiography (Pistenma et al, , 1975? Gitrin et ad., 1975).
Using this procedure Front and coworkers identified 155 sites of bony 
erosion in 190 patients with advanced breast cancer (Front et al., 1979)*
Only one third of these were painful. In comparison, Gardner and (Iordan 
(1962) found that urinary calcium was not significantly greater in patients 
with osteolytic disease and concluded that this was not a reliable index 
of progression ©r regression of osteolytic metastases from mammary carcinoma.
Hypercalcaemia may occur in the absence of skeletal metastases. Under 
these circumstances, there is evidence that the tumour is producing an 
osteolytic substance. Experimentally, when the tumour is implanted 
subcutaneously over the skull of a rat, local bony resorption will occur. 
Furthermore, a lipid extract of this tumour has been prepared, which when 
administered to a parathyroidectomised rat could induce osteolysis and 
hypercalciuria (Gordan et al., 1966). Chemically, it is similar but not 
identical to 7-dehydrocholesterol which is a precursor of vitamin B y Two 
osteolytic sterols have been extracted from human breast tissue and from 
plasma; these have been positively identified as A7 sitosterylacetate and 
sigmesterylacetate (Gordan, 1967). In isolated cases, tumour tissue has 
been found to produce parathyroid-like substances, generally in the absence 
of skeletal metastases. Clinically hypercalcaemia either occurs 
spontaneously, or it can be associated with the beginning of hormone 
therapy (Herrmann et al., 1949). The signs and symptoms associated with 
levels of calcium in the blood include gastrointestinal 
disturbances, mental changes and renal impairment. Anorexia, nausea and 
vomiting became persistent in the 4 patients with osteolytic metastatic 
breast carcinoma described by Swyer et al. (1950).
1.2.2 Hydroxyproline Metabolism
Hydroxyproline, a non essential imino acid is one of the unique 
constituents of collagen. It is excreted in free and bound forms in human 
urine (Eiff et al., 1956; Prockop and Sjoerdsma, 1961)* I*1® f*®® form 
normally makes up only 4 per cent of the total. The remaining hydroxyproline 
can be released from its bound form (polypeptide) by acid hydrolysis. 
Measurement of urinary excretion of total hydroxyproline has been used
extensively as an index of collagen degradation (Prockop, 1964; Prockop 
and Kivirikko, 1968). The sources of urinary hydroxyproline in man are 
outlined in Fig 4 (Roberts et al., 1975)• Standard conditions for studying 
hydroxyproline excretion are provided by 24 hour urine collections whilst 
on a low collagen diet (Prockop and Sjoerdsma, 1961). Rapid collagen 
turnover is found in association with a high metabolic rate and thus may 
explain the abnormally high daily hydroxyproline excretion found in 
hyperparathyroidism and during childhood and adolescence (Kivirikko et al., 
1965; Danelatos - Athanassiadis et al., 1969) otherwise there is little daily 
variation in hydroxyproline excretion (Prockop and Sjoerdsma, 1961).
Bone contains approximately 50 Per cent of the total body collagen 
and increased urinary excretion has been reported in disorders affecting 
the bone such as hyperthyroidism (Dull and Henneraan, 1963), hyperpara­
thyroidism (Benoit et al., 1963)> Paget's disease of the bone (Klein et al., 
1964) and rheumatoid arthritis (Ziff et al., 1956)• Hydroxyproline 
excretion rates have been reported in a number of cases of malignancy with 
and without bone involvement (Bonadonna et al., 1966; Hosley et al,, 1966; 
Roberts et al.* 1975; Heller et al., 1979). Platt and coworkers (1964) 
demonstrated that the extent of urinary hydroxyprolinuria in a series of 
patients with metastatic carcinoma of the bone seemed to correlate with 
the degree of activity of the skeletal deposits. In 1969 a group leal by 
Guzzo reported that the urinary hydroxyproline excretion was a more 
sensitive index of bony erosion than hypercalciuria and that in 10 patients 
with breast and bronchial carcinomata, an elevated excretion of this amino 
acid predated by several months the demonstration of osseous deposits by 
skeletal X ray. A greater proportion of breast cancer patients without 
radiological evidence of bone involvement with positive bone scans had a 
raised hydroxyproline/creatinine ratio (Guschieri and Felgate, 1972;
Roberts et al., 1975). 28 similar patients with positive bone scans excreted 
significantly elevated levels of total hydroxyproline compared to those
Fig. 4 SOURCES-OF URINARY HYDROXYPROLINE (ROBERTS et al, 1975)
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with normal scintigrams and benign disease (Sumner et al., 1973). In a 
sequential study where patients with breast cancer had repeated estimations 
of urinary hydroxyproline, elevated excretion of this imino acid was 
found to persist in those patients who later developed radiologically 
demonstrable metastases (Cuschieri, 1973)* Coombes and collegues (1977) 
suggested its use as a marker for the presence of skeletal metastases since 
scintiscanning requires expensive equipment which is not universally 
available. Hydroxyprolinuria has been correlated with increased mortality 
in these patients (Cuschieri, 1975? Roberts and Baum, 1975)* Powles et al., 
(1975) found that hydroxyproline excretion was useful in monitoring the 
progression of metastatic cancer of the breast and later demonstrated that 
dietary influence on its excretion could be eliminated, if determinations 
were carried out on samples which had been collected after an 8 hour fast 
(Powles et al., 1976). This is of considerable advantage for preoperative 
assessment where overnight fasting is easily organised, but strict dietary 
control for several days is difficult. As a routine follow up technique 
the reliability of bone scanning has been questioned (Bishop et al., 1979) 
and it has been suggested that urinary hydroxyproline would provide an 
alternative index of osseous deposits (Coombes at al., 1977).
1.2.3 Ascorbic Acid Metabolism
1.2.3*1 In Cancerous States
Generally, it has been shown that physiological desaturation of ascorbic 
acid can occur in several diseased states (Wilson, 197*0 • In fact, leucocyte 
ascorbic acid levels are highly sensitive to the state of health of the 
patient (Maclennan and Hamilton, 1977). Patients with malignant disease have 
been reported to have minimal tissue stores of vitamin C and many of these 
patients are frequently associated with physical signs compatible with 
sub-clinical scurvy (Bodansky et al. , 1951? Krasner and Dymock, 197*0. This 
has further been confirmed by studies on patients with leukaemia and a
variety of other neoplasms (Kakar and Wilson, 197^; 1976? Kakar et al., 1975)*
An early study revealed that patients with metastatic cancer utilise twice
as much ascorbic acid as either the control subjects or the patients with
localised disease (Minor and Ramirez, 19^3)* Recently it has been demonstrated
—8that the highest leucocyte vitamin G levels (33 £tg 10* WBC) was associated
—8with healthy subjects, whilst the lowest levels (12 ;ug 1CT WBC) with 
breast cancer patients bearing skeletal metastases. Intermediate values 
were found for patients with non malignant diseases and with those with 
nondisseminated malignant disease (Basu et al., I97^b).
In excised specimens of skin tumours ascorbic acid levels have been 
found to be significantly elevated (Moriarty et al., 1977» 1978)• Ghinoy 
(1972) reported similar findings and using histochemical techniques 
demonstrated that the greatest concentration of ascorbate was deposited at 
the periphery of the tumour against the actively growing margin. A 
corresponding reduction takes place in the adjoining non cancerous tissue 
and in blood ascorbic acid concentrations (Table k). It has been shown that 
ascorbic acid reserves are more rapidly exhausted in tumour bearing than 
in normal guinea pigs (Watson, 1938)• Furthermore the content of this 
vitamin in tumour tissue of experimental animals is high (Musalin et al., 
1936). Dyer and Ross (1951) studied the ascorbate concentration of tissues 
of mice bearing a wide variety of tumours, and in all examples the ascorbate 
concentration was greater in the tumour than in the liver of the respective 
host. Dodd and Giron-Conland (1975) using electron spin resonance have 
demonstrated that the ascorbyl radical is present in a wide variety of 
tumours in higher concentrations than in the corresponding normal tissues. 
However, for tumours the mean cell count per unit area was 216 compared 
with 28 for normal breast tissue, A 7 fold increase (Ellis et al., 1965) 
and when neoplastic accumulation of labelled androgens was expressed in 
terms of cell uptake rather than as uptake per unit wet weight the 
radioactivity in normal breast tissue was significantly higher than in 
tumour tissue.
Table 4. Studies Carried Out Contrasting Blood Ascorbic Acid Values 
in Cancer Patients and Normal Controls
BODANSKY et al.
(1951)
TYPES OF NO. OF
CANCER PATIENTS
Miscell- 69 
aneous
PLASMA LEVELS LEUCOCYTE IEVELS 
mg/lOO ml jug XO’8 cells
CANCER CONTROLS CANCER CONTROLS
0.48 0.79 27.0 36.le
WALDO AND ZIPF 
(1955)
30 0110 0.8 35
FREEMAN et al. 
: (1957)
0.62b 0.88b
KRASNER AND 
DYMOCK (197*0
■5P H.5 29.5
BASU et al.
(1974to
Advanced
Breast
Cancer
22 12 33
CAMERON
(1975)
Miscell­
aneous
24 0.26 O.96 11.2 24.3
WALDO AHD ZIPF
(1955)
Leukaemia 0.21 0.69
LLOYD et al. 
(1972)
Acute
Leukaemia
8 0.3 0.79 12° 35°
11 II II Chronic
Leukaemia
8 0.7 0.79 31 35
KAKAR et al.
(1975)
Acute Lym­
phoblastic 
leukaemia
10 0.4 0.95 35.9 56.4
BASU et al. 
(1974 t)
Miscell­
aneous
26 17 33
a expressed as mg per lOOg leucocytes
b values in whole blood
c values for platelets
The necessity of ascorbic acid for the maintenance of the normal and 
cancerous cell growth has been well documented. Vitamin C is thought to 
affect cell division (Edgar, 1970) and increase the activity of 3'-5* 
cyclic AMP and in consequence HNA transcription (Lewin, 1974) and 
influence glycosaminoglycah synthesis. In a recent study, biopsy material 
from an epidermoid carcinoma of the mouth of a 5^ year old Caucasian was 
set up in culture and subsequently a stable line of epidermoid carcinomatous 
cells was established. The addition of 600 /ig ml~^ or more of vitamin G to 
these cells resulted in an increased ratio of dead to live cells and a 
decreased rate of DNA synthesis (Bishun et al., 1978)• The function of 
ascorbic acid in collagen synthesis has been reviewed by a number of authors 
(Gould, 1968; Barnes and Kodicek, 1972). Originally it was thought that 
its most likely role was in the formation of collagen hydroxyproline 
through hydroxylation of proline before the latter was incorporated into 
the peptide linkage (Robertson, 1961). It is known from studies utilising 
isolated collagen synthesising systems that ascorbic acid does, as thought 
possible, participate in this reaction and also in the analogous reaction 
leading to the formation of collagen hydroxylysine; but the hydroxylation 
of both proline and lysine occurs only after the pertinent amino acid has 
been incorporated within the collagen polypeptide chain formed during 
collagen protein synthesis. However there remains some confusion about the 
effect of vitamin C deficiency on urinary excretion of collagen-derived 
fragments. An early study (Martin et al., 1961) reported a marked fall in 
daily hydroxyproline excretion in acutely scorbutic guinea pigs, but a 
later one (Barnes et al..1969) attributed this decrease to inanition, 
since it was closely matched by a similar decrease in pair-fed control 
animals. Recently, Bates (1979) has found that collagen probably turns over 
more rapidly in scorbutic guinea pigs and the increase in the proline/ 
hydroxyproline ratio in collagenase digests of the acetone-insoluble fraction 
could represent the rapid turnover of underhydroxylated nascent collagen. In 
human subjects, a moderate increase in hydroxyproline/creatinine ratio was
observed during mild experimental vitamin C deficiency, followed by a slow
return towards normal when vitamin G stores were repleted (Burkley, 1968)
a
and a single subject with hydroxyprolin^mia responded to vitamin G 
deprivation by an increase in excretion of this imino acid (Efron et al., 
1968). Windsor and Williams (1970) observed an increase in hydroxyproline/ 
creatinine excretion after vitamin G supplementation of elderly human 
subjects with initially poor vitamin C status. However, Basu et al., (1974b) 
recorded a decrease in the initially high hydroxyproline/creatinine ratios 
seen in patients with bony metastases after the administration of lg 
ascorbic acid. Arising from this Bates (1979) concluded that urine was 
unlikely to provide a specific and sensitive function of vitamin G status 
since it contains the degradation products from collagen of many tissues 
which differ widely in sensitivity to vitamin C. From the foregoing 
discussion it would seem that cancer patients have an increased 
requirement for the vitamin. Loading tests have suggested an increased 
utilisation of ascorbate by the cancer subjects (Basu et al., 1974b; Cameron, 
1975)• The combined results of all these studies show serious deficiencies 
of blood and leucocyte ascorbic acid to be a characteristic feature of 
cancer. Several authors have suggested that replacement of this deficit 
should be part of all comprehensive cancer treatment regimens.
1.2.3.2 Clinical Trials in the Management of Human Cancer
Reports published as early as 1940 underlined the clinical benefit of 
moderately large doses of ascorbic acid in cancer patients. Deucher (1940) 
claimed that from 1 to 4g of supplemental ascorbate per day was of definite; 
palliative benefit and also appeared to potentiate the beneficial effects 
of radiotherapy. Greer (1954) described the management of 1 patient with 
alcoholic cirrhosis later complicated by myelogenous leukaemia by ascorbic 
acid administration of levels ranging between 24.5 - 42g daily. In the 
previous year it was reported that the majority of 200 advanced cancer 
patients experienced pain relief from secondary deposits in the bone and a 
diminished reliance on morphia following the administration of a
supplementive preparation of zinc, magnesium and ascorbic acid (Meyer and 
Exner 1953)* Later, attention was drawn to work describing dramatic relief 
of bone pain in 4 out of 5 patients with expanding skeletal metastases 
(Cameron and Baird, 1973)* Soon after, results of a clinical trial of 50 
consecutive advanced cancer patients given supplemental ascorbate (lOg 
daily) were published (Cameron and Campbell, 1974). The paper claimed 
objective and subjective benefit in many of the patients, although in some, 
no benefit could be detected, whilst in three there was a strong suspicion 
that the administration of ascorbate had actually accelerated death. The 
autopsies of these latter patients showed wide-spread hemorrhage and necrosis. 
The paper lists the benefits, relief from pain, greater well being, a 
decrease in malignant ascites and malignant pleural effusions, relief from 
^maturia, some reversal of malignant hepatomegaly and malignant jaundice 
(about 30 per cent), decrease in erythrocyte sedimentation rate and decrease 
in the serum seromucoid level, all accepted indications of lessening 
malignant activity. The authors subjectively concluded that many of the 
patients survived longer than reasonable clinical expectation. However, in 
the absence of untreated matched controls it is impossible to conclude 
that the administration of ascorbic acid alone significantly prolonged the 
life expectancy of the cancer patients studied.
The same group of workers recounted the case history of a gravely ill 
patient with reticulum cell sarcoma, who was started on supplemental 
ascorbate (lOg per day) in October 1973> and who responded very dramatically 
with complete remission of all signs and symptoms of malignant disease 
within weeks (Cameron et al., 1975). The response of this particular patient 
was so dramatic and so complete that, in spite of positive histological 
confirmation of the diagnosis serious doubt was entertained about the 
correctness of the original diagnosis. Accordingly the vitamin supplement 
was withdrawn and indisputable signs of malignant reactivity returned. In 
a later report, 50 patients who had previously received irradiation and
chemotherapy were combined with the first group (Cameron and Campbell, 1974), 
and the survival of all 100 patients was compared with that of 1,000 
historical control cases in the records at the Vale of Leven Hospital,
Loch Lomondside, Scotland (Cameron and Pauling, 1976). For each ascorbate-
treated patient, 10 controls were matched on the basis of age, sex, site
/
and histologic features of the primary tumour. The mean survival of patients 
given ascorbate was 210 days, as compared with 50 for the selected controls. 
Since this was not a randomised study, doubt has been raised concerning the 
comparability of ascorbate treated patients and the control population 
(Comroe, 1978). Cameron and Pauling therefore revised the original study to 
exclude 10 ascorbate-treated patients with unusual cancers; they substituted 
10 other patients randomly selected from the records of ascorbate-treated 
patients at the same hospital (Cameron and Pauling, 1978). In addition, a 
new group of 1,000 controls was selected because data on*some of the initial 
control patients were considered unreliable and incomplete. Most of the new 
controls, however, were drawn from the original control population. This 
revised and updated analysis showed that the mean survival of patients 
given vitamin C was greater than 293 days as compared with 38 for the 
controls.
Since bias is possible in non randomised studies including selected 
controls, Creagan et al. (1979) conducted a randomised, controlled double 
blind trial involving 150 patients with advanced cancer. In this selected 
group of patients, the authors were unable to show a therapeutic benefit 
of high dose vitamin C treatment.
1.2.3*3 Possible Toxic Effects
Arguments against administration of large doses of ascorbic acid arise 
from evidence of resulting side effects (Wilson, 1974). Bamess (1977) 
has listed the reported toxic effects of vitamin G (Table 5)* Most concern 
has been shown over the possible development of acidosis and the production 
of oxaluria.
Table 5* Reported Toxic Effects of Vitamin G (Bamess, 1977)
Acidosis 
Oxaluria 
Renal Stones 
Glycosuria
Renal tubular disease 
G.I. disturbances 
Sensitivity
It appears that ascorbic acid ingestion is one of the contributory 
factors involved in urinary caliculi formation. Studies involving 
radioactive vitamin C have indicated that 5 per cent of urinary oxalate 
is derived from ascorbate (Burns et al., 1951; Heilman and Bums, 1958; 
Atkins et al., 1963; Gambardella and Richardson, 1977)t this represents 4*0 
per cent of the metabolic turnover of ascorbic acid (Atkins et al., 1963). 
However, the number of reports of urinary stone formation following ascorbic 
acid prophylaxis have been small (Briggs et al., 1973)* Klenner (1971),
Poser (1972) and Hoffer (1973) concluded from their wide experience of 
prescribing multigram daily doses of ascorbic acid - where they noted no 
patients who suffered calcium oxalate stone formation - that such hazards 
were very remote. Takenouchi et al.,(1966) found no significant elevation in 
urinary oxalate excretion on administration of up to 3g daily ascorbic acid 
for 2 consecutive weeks. Murphy and Zelman (1965) also concluded that the 
hazard of oxalate caliculi formation was minimal.
Similar apprehension has been directed towards the probability of uric 
acid stone occurence. Fox et al. (1977) demonstrated that the long term 
therapy with ascorbic acid, 8g per day, can lower the serum uric acid. Pena 
et al. (1963) found an increase of about 10 per cent in uric acid 
concentration following megavitamin G administration together with a small 
increase in blood uric acid concentration; these were accompanied by
Conditioned need
Prothrombin
Cholesterol
B^2 destruction
Laboratory errors
Fatigue
Sterility
approximately 1.5 times increase in the excretion of uric acid. Such a 
pattern suggests that any increase in vitamin G administration greatly 
potentiates uric acid excretion to an extent significantly greater than 
that of its increased blood levels. Lenin (1976) found this difficult to 
correlate with an increased probability of uric acid stone development.
Some recent studies on the metabolism of ascorbic acid have suggested 
that an excess Intake of the vitamin may lead to other side effects. Baker 
et al. (1971) have reported that ascorbic acid is in part metabolised to 
ascorbic acid sulphate, and in subsequent studies Houston and Levy (1975) 
have shown that if ascorbic acid and salicylamide are given together, the 
metabolism of the latter through sulphate conjugation is inhibited.
Basu (1977) demonstrated that the administration of megadoses of, ascorbic 
acid reduced the urinary excretory levels of cysteine. It was postulated 
that the amino acid acting as a sulphate donor was utilised to metabolise 
the vitamin, and since the degradation of cyanide may require cysteine 
(Basu, 1977) it was suggested that the catabolism of this toxin may be 
inpaired. Thus patients receiving chemotherapy with low protein intakes 
are not only exposed to the toxicity of the drugs which are detoxified 
through conjugation with sulphate but also to depletion of nutritional 
substrates.
Gastro-intestinal disturbances are perhaps the most consistent 
abnormalities noted following the ingestion of large quantities of ascorbic 
acid. Goldsmith (1971) reported that a daily intake of lg ascorbic acid 
may cause diarrhoea. The majority of 7 patients ingesting 3g of the vitamin 
daily experienced abdominal colic and some looseness of the bowels.
Regnier (1968) stated that some heartburn could be caused in some individuals 
(and that this could be relieved by a small amount of bicarbonate), and 
that after several days of high vitamin G dosage excess abdominal gas 
formation was possible. Cameron and Campbell (1974) refer to the aggravation of 
dyspeptic symptoms such as heartburn, nausea and acid regurgitation following
megadose ingestion in 2 out of 7 cases of cancers of the alimentary tract. 
Campbell and Jack (1979) specifically describe potentially dangerous 
symptoms in 3 cancer patients following oral ingestion of lOg ascorbic acid 
per day. Conversely 10 patients with carcinoma of the skin tolerated 6g 
of vitamin C daily for one week without any symptomatic ill effects 
(Moriarty et al., 1978).
1.2.3.4 The Possible Role of Ascorbic Acid in Anti-cancer Therapy
One of the possible ways in which anti malignancy potential of vitamin 
C may be mediated is through enhancing host resistance to spread of the . 
cancer (Cameron and Pauling, 1974). Cameron (1966) postulated the possibility 
of enhancing the production of a physiological hyaluronidase inhibitor 
to control the hyaluronidase liberated by the tumour, and thus preventing 
infiltration of the surrounding tissues. It became clear, however, that 
ascorbate might function in a number of ways to potentiate the various 
natural protective mechanisms of the body. Some of these have been discussed 
in earlier publications (Cameron and Pauling, 1973; 1974). In addition, an 
extensive discussion of the properties of ascorbate that bear upon its use 
in controlling cancer has been given in a review article (Cameron et al., 
1979). Among the factors involved in host resistance to cancer are the 
integrity of the glycosaminoglycan and proteoglycan intercellular matrix, 
the passive role of collagen in strengthening the matrix and its active 
role in the protective encapsulation of tumours, the control of invasive 
enzymes, hormone balance, immunocompetence and phagocytosis with ascorbic 
acid involved in all.
Considerable interest has been shown in the role of ascorbic acid in 
the immune response. Patients maintained on long term immunosuppressive 
regimens have an increased incidence of certain forms of cancer, and 
cancer patients tend to have decreased immunocompetence as measured by 
standard tests (Roitt, 1974). The immunological defence system is dependent 
on recognition of minute differences in molecular structure between various
foreign bodies. For such a system to work, cancer cells must display a 
surface antigen 'for recognition' different from their non neoplastic 
compatriots. For certain experimental tumours induced by specific 
onocogenic viruses and specific chemical carcinogens there as clear 
evidence that this is so, and furthermore the antigen is specific for the 
carcinogenic agent (Currie, 1974). In human cancer the picture is less 
clear. The immunocompetence mechanisms are a combination of humoral and cell 
mediated defensive reactions utilising immunoglobulins. The complement system 
is manufactured in order to challenge a specific antibody. The cascade of 
complement factors thus set in motion produce a variety of chemical 
transmitters and the indirect activation, through anaphylotoxin (Conrad 
and Feigen, 1975) of other cells to induce the release of activators to 
sustain the inflammatory response, phagocytosis. The reticuloendothelial 
system is concerned with the precise design and production of 
immunoglobulins. These are the humoral factors involved in the immune 
reaction. In cell mediated immunity, immunocompetence is exercised 
overwhelmingly by the lymphocytes. In tumours the degree of stromal 
lymphocyte infiltration is a measure of the efficiency of host resistance. 
Certain of these cellular immune functions in vivo and in vitro and humoral 
factors have been shown to be altered by vitamin C. Change in motility of 
normal neutrophils (Goetzl et al., 1974) and monocytes (Sandler et al.,
1975) and correction of abnormal neutrophil motility after ingestion of 
ascorbate has been reported (Boxer et al., 1976). Ascorbic acid mediates 
stimulation of polymorphonuclear leucocyte (PM) hexose monophosphate 
shunt activity (HMS) (De Chatelet et al., 1972). However, Shilotri and Bhat 
(1977) have reported that high doses of vitamin C caused a depression of 
the bactericidal capacity of normal human PMN. Lymphocyte functions are 
also reportedly affected by vitamin C (Panush and Delafuente, 1979). In 
vitro inhibition of human blood lymphocyte transformation to 
phytohaemagglutinin (PHA) by ascorbic acid at fairly high concentrations 
of ascorbic acid have been described (Munster et al., 1977). However,
substantial stimulation of lymphocyte transformation after the ingestion 
of vitamin C in mice has been reported (Siegel and Morton, 1977).
Ascorbate can also mediate enhancement of interferon production in vivo 
(Siegel, 1974) and in vitro (Siegel, 1975).
Basu (1979) has provided evidence to highlight the possibility that 
vitamin G in megadoses may arrest tumour growth by interfering with the 
metabolism of neoplastic cells. The author has postulated the involvement 
of the vitamin in decreasing the bioavailability of amino acids and zinc 
and increasing the tissue levels of cyclic AMP, all of which are 
deterrent to neoplastic growth.
The protective effect of vitamin G on the collagen of bone has been 
discussed and the reversal of hydroxyproline excretion in patients with 
skeletal metastases after ingestion of ascorbic acid (Basu et al., 1974 b) 
highlights to some extent the mechanism through which vitamin C in 
megadoses may alleviate pain from bone metastases (Cameron and Baird, 1973). 
However, Dickerson and Basu (1977) suggested that the reduction of bone 
pain was due to the effect of ascorbic acid on the conversion of tyrosine to 
L-dopa which in turn suppresses prolactin levels (Malarkey et al., 1971; 
Kleinberg et al., 1971). Thu^ high prolactin levels found in the 
development of breast cancer and later metastatic pain may be reduced by 
the action of increased L-dopa synthesised under the action of circulating 
ascorbic acid.
1.2.3.5 Animal Experiments
The ubiquitous nature of ascorbic acid has made it an unlikely 
candidate for it having any relevance to the problem of cancer. Arising 
from this, comparatively little work has been done on its effects on the 
incidence, induction and growth of experimental tumours. Moreover, the 
reports which do exist relating to in vivo experiments against animal 
tumours are often confusing and difficult to interpret. Guinea pigs
like humans do not synthesise their own vitamin C, whereas mice and rats 
possess ascorbate synthesising ability.
The transplantation of mice or rat tumours and the exposure of such 
animals to chemical carcinogens such as 3 - methylcholanthrene,
1, 2, 5,6-dibenzanthracene and 3,4-benzpyrene evoke a multifold increase in 
ascorbate synthesis (Burns et al., 1954). Kennaway et al. (1944) found 
carcinogenic compounds injected intraperitoneally caused an increase in the 
concentration of ascorbic acid in the liver of mice. Boyland and Grover 
(1961) showed that the rate of conversion of L - galactono -y- lactone into 
ascorbic acid was the same in microsomes from normal rats and rats treated 
with 1, 2, 5?6-dibenzanthracene, which caused increased excretion of the 
vitamin in the whole animal.
Many drugs are known to exert effects on the metabolism of ascorbic acid 
(Burns et al., 1954; Axelrod and Martin, 1961). Some of these drugs increase 
the formation of L - ascorbic acid, while others exert inhibitory effects 
on its biosynthesis (Minesita et al., 1959; Chatterjee et al., 1972: 
Sengupta et al., 1978).
Rats and mice bearing tumours have some enhancement of ascorbate
synthesis, but this is clearly insufficient to confer complete protection
and it is questionable whether any additional benefit could be derived
from administration of the vitamin. Supplemental ascorbate given to mice
caused
and rats has been shown to retard and sometimes inhibit carcinogenesis/^by 
3 - hydroxyanthranillic acid, carcinogenic nitrosamines and benzo(a)pyrene 
(Kallistratos and Fas'ske, 1980). Soloway et al. (1975) reported some 
inhibition of N - (4-5 nitro - 2 furyl) - 2 - thiazole formamide induced 
mouse bladder cancer. It is possible that the reducing power of ascorbic 
acid accounts for any inhibitory action and indeed it has been claimed 
that the vitamin removes available nitrite by its reduction to nitric oxide 
(Mirvish et al., 1976). Another mechanism by which dietary ascorbic acid
could exert an effect on chemical carcinogenesis is by its influence on 
mixed function oxidases and other enzyme - catalysed pathways. Considering 
the extensive literature on vitamin G and drug metabolism, one might 
expect to find evidence of parallel effects on carcinogen metabolism.
With regard to the effect of additional ascorbate on the growth of 
established tumours, Brunschwig (1943) indicated no significant effect. 
However, Omura and his associates (Omura et al., 1973) have reported that 
ascorbic acid and its metabolites exibit significant inhibitory effects 
orv the 'take1 and growth of transplanted sarcoma - 180 in mice. Russell 
et al. (1952) demonstrated shortening of tumour induction time in scorbutic 
guinea pigs treated with 3 - methylcholanthrene and growth and spread of 
such tumours was accelerated in these animals. However, in a later study, 
guinea pigs maintained on a ; !very low intake showed tumour regression; 
whereas those given the dose, lg per kg body weight daily, showed tumour 
enhancement (Migliozzi, 1977). The author concluded that ascorbic acid is an 
indispensable requirement for tumour growth.
1.2.4 Tryptophan Metabolism
There are many reports of abnormal tryptophan metabolism in patients 
with breast cancer (DeGeorge and Brown, 1970» Rose and Randall, 1972;
Davis et al., 1973). Rose (1967a) examined patients treated for breast cancer 
by mastectomy, who were free from any recurrence of the disease, and 
found abnormal tryptophan metabolism with an increased excretion of 
3 - hydroxykynurenine and xanthurenic acid in over half the patients studied. 
Similar findings were reported in women with breast neoplasia after a 
tryptophan load by Price et al. (1955) and Khalafallah and Abul - Fadl (1964).
Similar changes have been demonstrated in pregnant women (Sprince et al., 
1951; Brown et al., 1961) and in women taking the contraceptive pill 
(Rose, 1966 a ). Brown and associates (1961) examined the excretion of these 
metabolites in 7 normal women at different stages of their menstrual cycle
and found a significantly higher level of 3 - hydroxykynurenine at ovulation 
compared to that occurring immediately after a menstrual period. Wolf et ad. 
(1970) treated male subjects with a combination of oestrogen and progesterone 
(Enovid) and found parallel changes in metabolism of this amino acid when 
compared to female subjects receiving the same compounds. It was concluded 
that the overall efficiency of conversion of tryptophan to niacin was 
enhanced in subjects ingesting these hormones. However, in one study these 
shifts in excretory patterns only became apparent following the administration 
of a 2g loading dose of tryptophan.
Vitamin B^ , in its cofactor form, pyridoxal phosphate (PLP) plays a 
vital role in tryptophan metabolism (figure 5)* Deficiency of this vitamin 
leads to an increase in urinary concentration of some metabolites of 
tryptophan, that is kynurenine, 3 hydroxykynurenine and their derivatives, 
xanthurenic acid and to a lesser extent kynurenic acid. The availability 
of PLP for kynurenase seems to be the limiting factor for the kynurenine 
pathway (Mason and Berg, I952). Tryptophan pyrrolase, the initiating 
enzyme in the kynurenine pathway is positively induced by its substrate 
(Knox, 1951) and the administration of glucocorticoids (Chytil, I97I), 
adenocorticotrophic hormone (ACTH) (Rose and McGinty, 1968) insulin (Schor 
and Frieden, 1958), histidine (Knox and Auerbach, 1955) adrenalin and 
histamine (Knox, 1951). Although this enzyme has not been demonstrated to 
be oestrogen dependant Rose (1966 b) proposed that these hormones exerted 
their effect through induction of the enzymes of the kynurenine pathway, 
which could lead to a relative deficiency of PLP cofactor, in the presence 
of a tryptophan load. Lepkovsky and Nielsen (1942) reported that rats fed 
on-a.Bg deficient diet excreted a green pigment, which was eventually 
shown to be the iron chelate of xanthurenic acid. Cartwright and associates 
(1944) reported that swine fed a pyridoxine deficient diet excreted increased 
amounts of kynurenine and xanthurenic acid, but not of kynurenic acid.
Low levels of liver kynurenase activity were found in B^ deficient rats
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(Dalgliesh et al., 1951) and this seemed to correspond to the severity of 
pyridoxine deficiency (Mason and Berg, 1952).
A number of studies-involving-the determination of erythrocyte 
aminotransferase activities have demonstrated that women who use oestrogen 
containing oral contraceptives have significantly poorer B^ status than 
non - user controls (Doberenz et al., 1971; Rose et al., 1973» Salkeld 
et al., 1973). Furthermore, abnormal tryptophan metabolism observed in these 
women has been corrected by the administration of pyridoxine (Rose 1966 b). 
Nelson et al. (1951) found pyridoxine deficient rats would maintain 
gestation to the 17th day in only 10 per cent of pregnancies, while similar 
animals injected with l.Opg of oestrone plus 4mg progesterone remained 
pregnant.to the 17th day of gestation in 90 per cent of pregnancies. A 
report in 1959 described an intense inhibitory action of the sulphate esters 
of oestrone, oestradiol and diethylstilbesterol on kynurenine transaminase 
of rat kidney and on the phosphorylase of rabbit muscle (Mason and 
Gullekson, 1959). Extension of this work (Mason and Gullekson, i960) lead 
the authors to discuss the possibility of the inhibition resulting from 
competition between the steroid conjugates and PLP for the apoenzyme. Since 
this effect can occur dm vitro at very low concentrations of the inhibitor 
it might also occur at the low concentrations of oestrogen conjugates 
that exist in the tissues of the animal tinder normal or abnormal conditions. 
Recently, it has been shown that in the presence of a saturating 
concentration of PLP, oestrone sulphate showed in vitro competitive inhibition 
of rat liver kynurenase (Wynick and Bender, 1981). Preliminary studies 
revealed similar results using oestrogen glucuronide, which is the 
principle human metabolite of oestrone.
It appears that an interaction between oestrogen (endogenous or 
exogenous) and B^ levels exists, imparting subtle effects on tryptophan 
catabolism manifested by elevated end product excretion. Thus, the 
abnormal metabolism of tryptophan found in patients with breast cancer may
be due to changes in oestrogen activity (Bulbrook, 1972). Rose (1967 a) also
looked at patients treated by mastectomy and oophorectomy and found that
the excretion of one or more of the metabolites was decreased in some
women, which suggested that removal of oestrogen activity decreased the_____
capacity of the conversion of tryptophan to nicotinic acid. A decrease in
excretion of N' -methylnicotinamide and nicotinic acid has been shown in
rats after oophorectomy, and this can be reversed by giving oestrone and
progesterone (Lojkin, 1956). In a proportion of oophorectomised patients
there were raised levels of metabolites in the urine, but this may be
accounted for by the increased production of oestrogen by the adrenal
gland seen in women after oophorectomy. Rose and Randall (1973 a) found a
decline in the level of excretion of 3“hy&roxykynurenine, xanthurenic acid
and 3“hydroxyanthranillic acid on retesting patients who had been free from
recurrent disease months or several years after mastectomy. However, abnormal
tryptophan metabolism persisted in several patients, which may be attributed
to continuing abnormal endocrine activity. DeGeorge and Brown (1970) 
that
suggested^ relationship exists between the extent of disease and raised 
levels of tryptophan metabolites in the urine, these were further found to 
be negatively correlated with the rate of recurrence (Bell et al., 1972).
A number of studies have been carried out to attempt to correlate the 
urinary excretion of steroids and tryptophan metabolites. Bulbrook and 
Hayward (1967), in a 5 year study situated in Guernsey collected urine from 
nearly 5,000 women between the ages of 35 and 55 years and investigated 
the levels of androgen and corticosteroid metabolites in 17 women who 
subsequently developed breast cancer. In a substantial proportion of these 
women the excretion of androgen and corticosteroid metabolites were abnormal. 
Bell et al. (1971) found the excretion of ll-deoxy-17 oxosteroid in relation 
to 17 dihydroxycorticosteroid tended to be negatively correlated with 
tryptophan metabolite levels in premenopausal breast cancer patients. Davis 
et al. (1973) found a similar relationship involving urinary etiocholanolone.
However, plasma and urinary cortisol seemed to be independent of any 
increase in tryptophan metabolites in patients with both localised and 
disseminated breast cancer. Further, results from the Guernsey study 
(Bulbrook, 1972) revealed that patients between 20 and 40 years, with benign 
breast disease also had subnormal excretion of 11- dCoxy-17 oxosteroids.
This has previously been-found in patients with localised and 
disseminated breast carcinoma (Cameron et al., 1970)* It therefore appears 
that there is a general underlying hormonal disturbance in patients with 
benign breast disease as well as in those with breast cancer. Once breast 
cancer is manifest, the androgen metabolite excretion is directly related 
to the clinical course of the disease. Patients with subnormal androgen 
excretion generally have a rapid rate of recurrence after mastectomy, and 
respond badly to adrenalectomy and hypophysectomy (Bulbrook, 1970). It 
would seem that tryptophan metabolism is affected and may be accounted for 
by hormonal imbalance caused by changes in androgens, corticosteroids and 
probably oestrogens.
It is apparent from the foregoing discussion that there has been 
considerable interest in the possible role of vitamin G in the management 
of cancer patients, but the evidence for benefit is somewhat contradictory. 
Moreover, none of these studies have concentrated on one particular type 
of cancer patient.
The work reviewed previously also revealed that tryptophan metabolism 
is abnormal in over half the patients with breast cancer. This is seen in 
the elevated excretion of certain tryptophan metabolites. However, little 
work has investigated the levels of total tryptophan in the plasma of 
these patients.
From the work of Basu et al. (1974 b ) it seemed promising to explore 
the role of ascorbic acid in breast cancer, particularly since the association 
between this vitamin and the integrity of collagen could be seen to affect
the process of bone dissolution brought about by bone metastasis during the 
advanced stages of this disease. It was decided to undertake a prospective 
trial of moderately high doses of ascorbic acid in patients with breast 
disease. That is to study its effects in early breast cancer patients, where 
the prognosis of the disease could be influenced and in patients with 
advanced disease where it was anticipated that bone pain if not the growth 
of metastases would be under examination. The project was made possible 
practically, due to the existence of close links between the Biochemistry 
Department, University of Surrey, Guildford and St. Luke's Radiotherapy 
Department, Guildford. One of the major aims was to study this set of 
patients longitudinally since the present information on serial determinations 
of plasma and leucocyte ascorbic acid and their relationship to bone 
metabolites is limited. In addition, opportunity was taken to attempt to 
elucidate the possible changes in tryptophan metabolism and to establish 
their transitory or permanent nature.
CHAPTER TWO
2. PATIENTS AND METHODS
2.1 Patients
It was decided to study three groups of patients. These weres
1. Patients with early breast cancer
2. Patients who have developed skeletal metastases from 
a breast primary tumour
3* A control group of patients with benign breast disease 
Initially the clinical study consisted of the first group.
2.1.1 Patients with Early Breast Cancer
A total of 52 newly diagnosed, histologically proven breast cancer
patients (all female, age range 32-78) have been included in the trial.
All these patients were contacted in Dr White's Clinic, which is held in
the Radiotherapy Outpatients Department, St. Luke's Hospital, Guildford.
This part of the study was initiated in March 1978 and the patients were
systematically enlisted until February of the following year. 28 of these
early breast cancer patients are taking 3g ascorbic acid per day in the
form of "Redoxon" (kindly donated by Roche Ltd), Each group of patients
was similarly randomly subdivided, so that patients with an even date of
birth received the vitamin and those with an odd birth year acted as
controls. It was possible to characterise 5° of these patients using the
TNM classification, which was either provided on referral or calculated
from available information concerning the size of the original tumour, 
{axillary lymph nodes’! 
presence of palpable etc. The pathological reports included
information concerning the appearance and degree of differentiation of the
original tumour with some appraisal of lymphocyte infiltration. Where
mastectomy was accompanied by the dissection of local lymph nodes the
degree of node involvement was provided. However, the amount of this
information varied from patient to patient depending on the requirements
of differing surgeons. The available data is summarised in table 6.
48 of these patients had been treated surgically for removal of the 
primary tumour. All patients underwent a 6 week radiotherapy course, prior
Table 6. Characterisation of Early Breast Cancer Patients
I Host Resistance (19)*
Number of 
Patients
Minimum Lymphocytic 
Response
8
Moderate Lymphocytic 
Response
4
Brisk Lymphocytic 
Response
7
II Degree of Differentiation (35)'
Poorly
Differentiated
Number of 
Patients
26
■t'
Moderately
Differentiated
Well
Differentiated
III Pathology (47)a
111*1 Infiltrating Duct Carcinoma - 46 patients 
7 described as schirrous carcinoma 
35 described as adenocarcinoma 
1 described as polygonal cell type 
1 described as spheroidal cell type 
1 described as medullary carcinoma 
1 described as anaplastic carcinoma
III.2 Infiltrating Lobular Carcinoma - 1 patient
IV TNM Classification (5l)a (This is determined using presentation
Number of 
Patients
W  Vo
38
Tl-V H0-1M0 
13
clinical data) 
Tl-4 » N0-l* M0-1
V Node Involvement (4l)‘
Number of 
Patients
Lymph node 
negative
18
Lymph node 
positive
23
a - refers to the number of patients for whom this information was available.
to which initial base line blood samples were taken. Each patient had been 
previously contacted by the Departmental Radiotherapist, and requested to 
supply an early morning fasting urine sample. The urine*sample was sent to 
the Hospital Biochemistry Laboratory for the determination of hydroxyproline 
content. On completing the course of inradiation a similar set of samples 
were taken from the patient. All patients were seen at a subsequent six 
weekly interval and then on 2 consecutive occasions separated by a follow- 
up period of 3 months. The blood samples have been analysed for plasma 
and leucocyte ascorbic acid, inorganic phosphate and alkaline phosphatase. 
Determinations of free and total tryptophan have also been carried out. The 
urinary end products of bone metabolism which have been measured are 
hydroxyproline, (in relation to creatinine), calcium and inorganic phosphate. 
Oxalate measurements have been carried out. In addition the three metabolites 
of tryptophan namely 5-hydroxyindoleacetic acid, N'methylnicotinamide and 
xanthurenic acid have been determined. In addition, indirect measurements 
of ascorbic acid status were carried out consecutively using the sub-lingual 
test described by Cheraskin and Ringsdorf (1968 a).
The progress of these patients has been closely observed and if any 
skeletal recurrence became obvious subsequent blood and urine samples were 
taken and similar measurements of ascorbic acid status and bone metabolism 
were carried out. The clinical trial is being continued and it is planned to 
retrospectively analyse the prognosis of disease in each of these patients. 
Any possible effects of the ingestion of vitamin G will be evaluated.
2.1.2 Patients with Skeletal Metastases
The recruitment of later stage metastatic patients commenced in September 
1979 and was carried out in Dr Earl's follow-up clinic in the same 
department of St, Luke's Hospital, Guildford. Patients were picked by 
virtue of their positive bone scan (in the presence of a negative liver 
scan) and were in the main endocrinologically controlled. 18 patients were 
enlisted (all female, age range 47-83). Initial ascorbic acid levels
(including plasma and leucocyte) and urinary determinations of hydroxy­
proline/ creatinine ratio were measured in 11 of these patients. This 
group was subdivided so that 6 patients were taking 3g ascorbic acid daily 
and 5 not. Three of these patients were originally in the early breast 
cancer group and were subsequently included in the metastatic group when 
skeletal deposits became demonstrable using bone scan techniques. The 
remaining 7 patients were examined sequentially with reference to 
hydroxyproline excretion. All of these patients were taking vitamin G.
These patients were followed up according to their clinical requirements,
consequently the time period between sequential blood samples for each
patient is different. This is in contrast with the early breast cancer
patients. This group of patients has been characterised by virtue of the
available information concerning the pathological type, degree of
differentiation, lymph node involvement and TNM classification A table 7)*
I response7
Unfortunately there was little indication offiymphbcytic' /y in the 
pathological report. The number of patients taking certain drugs or 
experiencing local radiotherapy over the period of study is indicated. Of 
these patients, 7 died over the period of study. These were the most 
difficult set of patients to follow up since the fragility of their bones 
and the advancement of their disease necessitated periods of hospitalisation 
elsewhere in the area.
2.1.3 Patients with Benign Breast Disease
A total of 24 patients were contacted in Dr Brient's breast clinic, 
which is held in the same department, St. Luke's Hospital, Guildford. 
Patients with a history of benign breast disease and whose mammograms had 
not shown any radiological evidence of malignancy were included in the 
study. These patients are clinically characterised in table 8.
Blood and random urine samples were collected from the first set of 10 
patients in March 1979* 5 of these patients were given a prescription for
Table 7. Characterisation of Metastatic Patients
I Degree of Differentiation (7)*
Poorly Moderately
Differentiated Differentiated
Number of Patients 
*a
Well
Differentiated
0
II Pathology (15)'
Infiltrating Duct Carcinoma - 14 patients
2 described as adenocarcinoma
3 described as schirrous carcinoma 
5 described as anaplastic carcinoma
Pagets disease of the nipple - 1 patient
III TNM Classification (I3)a (This is determined using presentation clinical
data)
T1-4N0M0 T1-4N0-1M0 T1-4N0-1M0-1
Number of Patients 5 8 0
IV Node Involvement (9)a 9 patients had previously not had surgery but
were histologically confirmed by biopsy methods
Number of Patients
V Treatment Regimens 
Patient Initial 
EB 
CB 
WB 
RC 
JD 
AP 
SS 
GS 
RO 
SG 
EM 
RN 
SJ 
EH 
WN 
DT
ET
JF
Lymph Node ~ve 
2
Lymph Node +ve 
7
Local Radiotherapy (RT) Drugs
Distalgesic, Feospan, Prednisolone, Dexamethasone, RT
Tamoxifen, Prednisolone
Tamoxifen, RT
Tamoxifen
Durabolin, RT
Tamoxifen, RT
Tamoxifen, RT
Durabolin, RT
RT
Tamoxifen, RT 
Tamoxifen, Distalgesic 
Neomercazole, Tamoxifen 
Tamoxifen, RT 
Tamoxifen 
Durabolin, RT 
Tamoxifen, Chemotherapy
Tamoxifen, RT 
Tamoxifen
a Refers to the number of patients for whom this information was available
Table 8 Characterisation of Patients with Benign Breast Disease
Patient Time Span of Sample Type of Breast Disease
Initial Collection
PA Oct 1979 Jan I98O Breast cysts
MG •• •• Breast Discharge
DS .• .. Mastitis
WS •• .. Breast Cyst
PM •• •• Fibrocystic Disease
BB .. •• Fibrocystic Disease
JA .. .. Inverted Nipple
GF •• •. Fibroadenosis
ED .. .. Cysts
PF .. .. Cysts
AC March, 1979 June 1979 Nipple Discharge
RW •• .. Mastitis
SH .. .. Breast Cyst
BM •. •. Nipple Discomfort
MG •• .. Fibrocystic Disease
ED •• •• Breast Cyst
MM •. •• Breast Cyst
MR •• •• Nipple Retraction
DR •• .. Breast Cyst
Cl .. Nipple Discharge
MJ June 1980 Sept I98O Benign lump over costal
condrol junction
CL •• .. Breast Discomfort
IB .. .. Breast Cysts
DP •• •• Breast Cysts
lg t.d.s. ascorbic acid per day. All patients were instructed to attend a 
follow up three month appointment, whereupon similar blood and urine 
samples were collected. *f patients did not attend and failed to arrive for 
subsequent appointments. Leucocyte and plasma ascorbic acid concentrations 
were determined within a week of sample collection and frozen aliquots of 
plasma were further analysed for total tryptophan, calcium and inorganic 
phosphate. Similarly, levels of tryptophan metabolites and oxalate were 
measured in urine samples, which had been frozen in the presence of 
glacial acetic acid. Later, k additional patients were included in this 
group |; they | were contacted in June I98O and similarly followed up as 
previously described. Half of these patients ingested 3g ascorbic acid 
daily for 3 months.
Hydroxyproline and vitamin C excretion were examined in 10 patients 
contacted in the same clinic under the same conditions. This study started 
in October 1979 when initial urine samples were collected at the clinic 
after a brief dietary history had been taken. Any of the patients who had 
ingested foods containing appreciable amounts of collagen were discounted. 
These initial urine samples were analysed for hydroxyproline, creatinine 
and ascorbic acid. All patients received lg t.d.s. ascorbic acid for 3 
months after which early morning fasting samples were collected and 
analysed for the same metabolites. One patient did not attend. Tables 9a 
and 9b show the number of determinations carried out on each set of patients,
2.1.*+ Kinetic Studies
Kinetic studies were carried out during September and October of 1980. 
These involved 3 groups of female patients as follows:
a) 5 Early Breast Cancer Patients
b) 5 Patients with Benign Breast Disease
c) 5 Normal Patients
All patients (except 2 normal controls) were postmenopausal. Group (a) 
was -chosen from those women already included in the early breast cancer
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study and consequently characterised as previously described. The 5 benign 
and control patients had not previously been studied. The latter were 
drawn from the university staff and the former from the Breast clinic at 
St. Luke's Hospital, Guildford.
The patients were instructed to bring an early morning urine sample
(which was taken after the first drink of the morning) to the Clinical
Investigation Unit, St. Luke's Hospital, Guildford. The patients received
a standard breakfast of toast, marmalade and coffee after which they
ingested a 3g dose of ascorbic acid (3 tablets of 'Redoxon' dissolved in
water). Thereafter, urine samples were taken hourly. Volumes were noted and
urinary extracts were frozen in the presence of %  trichloroacetic acid.
The vitaminJ2_analys.es were carried out within 3 days of the loading test 
[expressed as
and the totalling excreted per hour after the loading dose was calculated.
The frequency of consumption of vitamin C containing foods was noted 
for each patient. From this the ascorbic acid content of the diet was 
estimated on the basis of low, moderate or high intake. Details of cigarette 
consumption was also recorded. (Table 10). None of the subjects had a 
history of high ascorbic acid intake.
2.1.5 Metabolic Profiles
In June 1979 & female patient (age 36) was referred to Professor 
Dickerson. At this time she possessed skeletal metastases situated in the 
pelvis, which had arisen from a lactating breast carcinoma. The primary 
lesion was identified as an intraduct and infiltrating duct carcinoma of 
extremely poor differentiation. Opportunity was taken to study this patient. 
Monthly blood samples were taken and analysed for leucocyte and plasma 
ascorbic acid, plasma calcium, inorganic phosphate and alkaline phosphatase. 
Serial urine samples taken at the same time were analysed for hydroxyproline 
and expressed in terms of creatinine excretion, ascorbic acid and calcium. 
The advancement and treatment of the disease in relation to each blood and 
urine sample collected is shown in fig. 6. During the period of study the
Table 10 Characterisation of Patients Included in the Kinetic Studies
Patient Initial Age Estimated Intake Cigarette Consumption
of Vitamin C
Early Breast Cancer Patients
LW
NS
KH
AC
FB
65
63
56
65
78
Low
Low
Moderate
Moderate
Low
Yes
Yes
No
No
No
Benign Patients
CL 60
MJ 52
BB 63
EP 59
SS 49
Low
Moderate
Low
Moderate
Moderate
Yes
No
No
No
No
Normal Controls
SW
SF
BW
JVJ
DD
71
69
39
4-3
61
Low
Low
Moderate
Moderate
Moderate
No
No
No
No
Yes
Figure 6. Clinical History of 36 year old Patient 
(P.W.) and Sampling Times.
April
June
Feb.
March
April
June
July
Aug.
Sept.
Oct.
Nov.
Dec.
Jan.
Feb.
March
April
May
June
1978
1978
1979
1979
1979
1979
1979
1979
1979
1979
1979
1979
1980 
1980 
1980 
1980
1980
1980
July 1980 
Aug. 22nd I98O
Lump first noticed in left breast
Primary radiotherapy to the breast
Bone scan showed increased uptake of isotopes in 
the pelvic area. Bone biopsy confirmed metastases. 
Local radiotherapy to the pelvis.
Oophorectomy
Tamoxifen
Prednisolone
1st BLOOD SAMPLE
2nd BLOOD SAMPLE
3rd BLOOD SAMPLE
4th BLOOD SAMPLE
5th BLOOD SAMPLE
6th BLOOD SAMPLE
7th BLOOD SAMPLE
8th BLOOD SAMPLE
9th BLOOD SAMPLE
Radiotherapy to the spine 
Adrenalectomy using aminoglutethimide.
10th BLOOD SAMPLE
Radiotherapy to the right pelvis 
11th BLOOD SAMPLE
ADMITTED TO THE ROYAL MARSDEN HOSPITAL, SUTTON. 
DIED.
patient was taking about 5g ascorbic acid daily.
2.2 Methods
2.2.1 Determination of Ascorbic Acid in Leucocytes, Plasma and Urine.
The leucocyte ascorbic acid level was measured in a sample of peripheral
blood by the method of Denson and Bowers (1961). The leucocytes were 
settled out in dextraven solution within minutes of collecting the blood in 
EDTA tubes, and white cell counts carried out on the resultant suspension 
using a coulter counter model S-plus (Haematology Department, St Luke's 
Hospital, Guildford). The leucocytes were harvested after 3° minutes, since 
prolonged incubation does cause an increase in cell content of ascorbic 
acid. The cells were resuspended in %  trichloroacetic acid (TCA) and the 
clear extract stored at -40°C for a maximum of one week before analysis, as 
it has been established that the stability of plasma ascorbic acid is 
enhanced when stored at a low temperature in the presence of TGA (Bradley 
et al., 1973)• Similar extracts were made for the plasma and urine samples 
which were collected at the same time and assayed by virtue of the coupling 
reaction involving ascorbic acid and 2-4-dinitrophenylhydrazine which yields 
a chromogenic compound (Roe and Kuether, 1943)* Each sample was estimated in 
duplicate and the average of two values taken as the result and expressed
Q
as jig per 10 white blood cells (WBC) for leucocyte, mg per 100ml for 
plasma and urine ascorbic acid. The proportionality of the colour obtained 
in this reaction is in excellent agreement with Beers Law over the 
concentrations studied. L-ascorbic acid in %  TGA was used as the standard 
for ascorbic acid. The standard curve is shown iri fig. 7*
2.2.2 Determination of Urinary Hydroxyproline (OHPro)
Urinary total hydroxyproline (OHPro) was determined by the method 
described by Nobbs et al. (1975), which utilises the adsorbing properties of 
Amberlite resin. The procedure was slightly modified as follows
An aliquot (0.5ml) of urine was autoclaved for 3 hours in the presence 
of 250mg of acid washed Amberlite resin. After cooling, the hydroxyproline
was eluted off under mildly alkaline conditions and the volume of each 
tube made up to 2.5ml with distilled water. To 0.5ml of the supernatant,
1.0ml propan-2-ol and 0.5ml fresh chloramine-T-oxidant solution was added. 
After vigorous mixing, the tubes were incubated at 60°C for 20 minutes and 
then cooled to room temperature. The absorbance was measured at 5^0nm 
against the reagent blank on a Gilford 300N spectrophotometer. The final 
result is expressed as a ratio of OHPro to creatinine (Cr) excretion,
OHPro : Or [OHPro] (mmole dm"*^ )
 ---------------- —  x 100
Ratio [Cr] (mmole dm"*'';
which when derived from an early morning fasting sample is representative of
basal OHPro excretion with minimum dietary influence (Powles et al., 1976)•
Chromatographically pure L-OHPro was used as the standard and the calibration
-3curve for concentrations ranging from 0.05 - 0.5mmole dm ^ is shown in fig 8.
2.2.3 Determination of Creatinine (Cr) in Urine (Automated Method).
Urinary Cr was determined by quantitating the orange pigment, alkaline 
creatinine picrate (Jaffe" reaction) using a Technicon Auto Analyser I. The 
sample stream, segmented with air is diluted with 0.<$ saline. This combined 
stream enters the sample side of the dialyser. The recipient stream consists 
of water segmented with air. After emerging from the dialyser, it is joined 
by picric acid and NaOH streams. These axe mixed, passed through a time 
delay coil and into the colorimeter. The developed colour is read at 520nm 
using a 10mm flow cell.
Z.Z.k Determination of Plasma and Urinary Calcium
Plasma and urinary calcium was measured by atomic absorption 
spectrophotometry. Plasma samples were defrosted, centrifuged and diluted 
1 in 50 in a solution of 0.1% (w/v) lanthanum (BDH lanthanum chloride 
solution for atomic spectroscopy) and aspirated into a Perkin Elmer 303 
atomic absorption spectrophotometer. Lanthanum effectively removes 
interference from phosphate and protein. Urine samples were diluted 1 in 100
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and similarly processed. Analar calcium carbonate (2.5mM) was used as the 
reference standard and a typical standard curve is shown in fig, 9. The 
following machine settings were useds- 
Wavelength 422.7nm
P. M. Voltage 530V
Slit Width 320pm
Lamp Current 7mA
2.2.5 Determination of Plasma and Urinary Inorganic Phosphate
The present study employed the method developed by Fiske and Subbarow 
(1925) for the determination of inorganic phosphate in plasma and urine.
This involves the production of an intermediate compound phosphmolybic 
acid which is reduced by the addition of 1.2.4 aminonapthosulphonic 
reagent to produce a blue colour. The optical density was measured at 660nm 
on a Cecil spectrophotometer. The standard curve obtained is shown in fig 10.
2.2.6 Determination of Oxalate in Urine.
Initially oxalate in the urine was determined indirectly using atomic
absorption spectrophotometry (Menache, : 1974). Theoretically, oxalic acid
24-in the urine is precipitated with excess Ca ions at pH 5* The excess 
calcium in the supernatant and the total calcium added and present in the 
urine at pH 2 are determined by atomic absorption spectrophotometry. The 
oxalic acid present in the precipitate is calculated from the difference 
between the two determinations of calcium. However, in this laboratory, it 
was found that the calcium levels of urine samples precipitated in duplicate 
were not similar, and the final oxalic acid results varied greatly from 
those published by the author. Modifications of this method (Koehl and 
Abecassis, 1976) which employed calcium and oxalic acid overload solutions 
again yielded indecisive results.
Thus, the procedure which was finally used was one based on the 
colo rimetric reaction described by Hodgkinson and Williams (1972). The
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method was modified as follows
Two drops of concentrated HC1 were- added to 2ml of urine. Following 
this 0.5ml acidified urine, 1.5ml double distilled water and 1 drop 0.4$ 
(w/v) bromothymol blue indicator was measured into a 40ml sovirel tube.
The pH was adjusted to 7*0 (green by the addition of dilute NaOH). An 
overload of 2ml of saturated aqueous solution of calcium sulphate was added, 
followed by 14ml absolute ethanol. They were then mixed gently and allowed 
to stand at room temperature overnight. The ethanol precipitation of 
calcium oxalate was carried out in duplicate.
The tubes were then centrifuged at 2,000 rpra for 10 minutes in a 
Beckman J6 centrifuge. The supernatant fluid was carefully decanted and 
the tube allowed to drain for a few minutes on filter paper. The precipitate 
was dissolved in 2ml 2N H^SO^. A piece of granulated zinc approximately 
2mm X 6mm was cleaned in freshly made 10N HNO^. After washing thoroughly in 
distilled water the zinc was added to the solution, and the tube was left 
uncapped and heated in a boiling water bath until the final volume was 
less than 0.5ml. The zinc was removed with a glass rod and washed with 
0.5ml of 1$ (w/v) chromatrophic acid. The washings were added to the tube 
followed by 5ml concentrated H^SO^ which was added slowly with mixing and 
heated in a boiling water bath for thirty minutes. The tubes were not 
stoppered. They were cooled and made up to 10ml with 10N H^SO^.
Potassium oxalate monohydrate (i.0231g) dissolved in 100ml of double 
distilled water gave a stock standard solution containing 5mg of anhydrous 
oxalic acid per ml and from this a range of dilutions (0 - 50)*g) were 
prepared. To 1ml of standard^lml 4N H^SO^ was added, plus a piece of 
freshly cleaned zinc and the procedure carried out as previously described.
A calibration curve was drawn plotting the optical density at 57Onm, read 
on a Cecil spectrophotometer, against ug of anhydrous oxalic acid (fig. ll). 
The concentration of oxalic acid in the original sample of urine was 
given by the equation:-
Concentration
(mg of anhydrous oxalic 
acid per 100 ml)
2.2.7 Determination of Alkaline Phosphatase and its Isoenzymes
in Serum (Automated)
Total alkaline phosphatase in serum was determined by virtue of the 
yellow p-nitrophenyl moiety produced after incubation with its substrate 
p-nitrophenyl phosphate (Boehringer Automated Analysis Autopack for alkaline 
phosphatase). The rate of colour production is measured using an automatic 
reaction rate analyser (Vitatron AKES).
The isoenzymes were separated using cellulose acetate electrophoresis 
(Fritsche et al,, 1972).
2.2.8 Determination of Plasma Total Tryptophan
The method used was a revised fluorimetric procedure described by Bloxam 
and Warren (1974) based on that previously established by Denckla and Dewey, 
(1967). The reagents and procedure were as described by Denckla and Dewey 
(1967), except for the following modifications. Plasma samples (usually 
50jil) were deproteinised by adding 2.0ml ice cold 10$ (w/v) trichloroacetic 
acid (TCA) and centrifuged at 4°C (20 mins X 2,500 rpm). The stock 
tryptophan standard solution (lOOpg/ml) was diluted to concentrations 
ranging from 2 to 10}ig/ml with 0.1N NaOH. 50jil aliquots containing up to 
5ug were added to 2.0ml 10$ TCA. To each protein free sample on ice or 
standard^  was added 0.2ml 2$ (w/v) formaldehyde and 0.1ml 6.0 X 10~^
FeCl^ in 10$ TCA. The time between deproteinisation of the plasma samples 
and transfer to the boiling water bath should be less than 60 - 90 minutes. 
Temperatures below 99°C seriously affect the yield of the fluorophore.
After heating for 1 hour the tubes were cooled to room temperature and 
made up to 3.2ml with 10$ TCA. The fluorescence of the norharman product 
was measured using a Perkin Elmer fluorescence spectrophotometer MPF-3 at 
excitation and emission wavelengths of 373nm and 445nm respectively. The
Reading from -nn
Calibration curve X n - X
(pS) °-5 1000
fluorophore is stable in the assay solution for one week. Fig. 12 shows a 
typical standard curve.
Identical methodology and equipment has yielded a mean recovery of 
added tryptophan from 4 human plasma samples of 96.8$ (range 89.2 - 109.4$) 
(Hardwick, 1976). It was further established that quantitative recovery 
depends on the thorough and reproducible denaturation of the protein, which 
is due to the affinity of tryptophan for plasma albumin.
2.2.9 Determination of 5-Hydroxyindolacetic Acid (5-HIAA) in Urine
Spectrophotometric techniques of determination have previously been
found to be unsatisfactory (Borounand-Naini, 1978)* hence a sensitive 
spectrofluorimetric method was employed. The procedure was slightly modified 
from that described by Contractor (1966)
The Sephadex column was prepared as originally described. Urine (lml) 
mixed with 9ml 0.1N HC1 was slowly washed through the Sephadex column, 
which was then washed with 10ml 0.1N HC1 followed by 5^1 of distilled water. 
The adsorbed 5-HIAA was eluted with 5^1 of 0.02N NH^OH. A 2ml aliquot of 
the eluate was mixed with 2ml 6N HC1 and its fluorescence was measured 
using a MF3 Perkin Elmer spectrophotometer set for excitation at 295nm and 
emission at 535nm. The fluorescence intensity has been found to decrease 
with time after the addition of 6N HC1, hence the readings were carried out 
sequentially within 15 minutes of the addition of the acid. Blank values 
were obtained by the addition of one drop of saturated aqueous potassium 
persulphate. A standard curve for the determination of 5-HIAA is shown 
in fig. 13.
2.2.10 Determination of Xanthurenic Acid in Urine.
Xanthurenic acid was assayed by virtue of the green complex formed on 
addition of ammonium ferric sulphate under set conditions(Rosen et al., 
1951). The procedure was modified from the original method to give 
greater reproducibility.
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Aliquots of urine (15ml) were accurately adjusted to between pH 7.3 - 
7*5 using a EIL 7030 pH meter and filtered through No 1 Whatman filter 
papers. A 2.0ml sample of filtered urine in new plastic 10ml tubes was 
diluted to 4.5ml with distilled water, which was similarly pH adjusted. 
Approximately 5 “ 8mg of sodium dithionite followed by 50jil of 1.7$ (w/v) 
FeNH^(SO^)g.IZHgO was added and the tubes inverted twice. Fresh sodium 
bicarbonate solution (0.5ml) was added and the tubes were mixed gently. The 
blank values were read at 620nm on a Cecil spectrophotometer. The colour 
complex was formed after mixing on a rotary mixer for 15 minutes and read 
a second time at the same wavelength as above. It was found that the 
stability of the urinary xanthurenic acid complex was greater (up to 3 
hours) than that of the pure xanthurenic standard solutions (up to 10 
minutes). Standard xanthurenic acid solutions dissolved in 5$ ethyl alcohol 
and adjusted to between pH 7.3 - 7*5 with NH^OH were prepared. A standard 
curve for xanthurenic acid is shown in fig. 3/f. Recoveries of pure 
xanthurenic acid ranged between 67% - 109$.
2.2.11 Determination of N'-Methylnicotinamide in Urine
N' -methylnicotinamide (NMN) was determined using the method described 
by Gyorgy and Pearson (1970). The procedure which was carried out in 10ml 
graduated tubes (Exelo) did not deviate from that originally set out by 
the authors. A range of standards (1.0 - 10.0 fig ml )^ of N'-methylnicotinamide 
were prepared (fig. 15). The ketone reagent should be added in the order 
designated, never in the reverse order. If NMN solutions are made alkaline 
in the absence of ketone, significant destruction occurs. Recoveries 
ranged from 70 to 100 per cent.
Urinary hydroxyproline, creatinine and serum alkaline phosphatase and 
resolution of its isoenzymes were all carried out in the Biochemistry 
Department, St Luke'js Hospital, Guildford.
All chemicals and reagents were obtained either from British Drug 
Houses or Sigma unless otherwise stated.
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CHAPTER THREE
3. EFFECTS OF ASCORBIC ACID ADMINISTRATION 
IN BREAST CANCER PATIENTS AND CONTROLS
3.1 Introduction
This chapter consists of two sections. The first presents the results 
of the administration of 3s per day of ascorbic acid (AA) on plasma and 
tissues (leucocyte) concentrations of the vitamin, associated kinetic 
studies and the urinary excretion of an ascorbic acid metabolite, oxalic 
acid. The second section presents the results of the determination of 
plasma and urinary metabolites which are indicators of skeletal metabolism.
Much of the literature concerning these aspects of the subject has 
been presented and other pertinent references will be included in the 
discussion.
3.2 Results
3.2.1 Effects on Plasma and Leucocyte AA Concentrations
The mean values! for the plasma and leucocyte AA concentrations of the 
different groups of patients are shown in Table 11. The initial values for 
all the patients varied considerably as indicated by the rather large 
standard deviations. However, the mean values for each of the four groups 
ranged only from 0.80 to l.lOmg lOOml” .^ Over the five visits, the mean 
values for the unsupplemented cancer patients did not change significantly, 
whereas the mean value for those receiving AA rose significantly! |p< 0;001) ■) 
and at each time interval, the mean concentrations for the patients that 
received the vitamin were higher than for those patients that did not.
1
Only one sequential value was obtained from those patients-with benign breast 
disease and that was 3 months after the initial visit*, • > ■,
, These showed changes which wereiimilar to those in
the cancer patients, with those patients not receiving the vitamins
showing no change and a significant rise | (P < 0.01) in those taking AA.
The initial mean leucocyte values for.patients with benign breast 
disease were lower than for those with breast cancer. This may be due to 
the fact that all the patients with benign disease were recruited during 
the winter months whereas those with cancer were recruited throughout the 
year. In contrast to the changes in the plasma AA concentrations in cancer
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patients, those for the leucocyte concentrations did not rise significantly 
over the course of the five visits and at no stage were values in the treated 
patients significantly higher than those of the untreated ones. However, 
the leucocyte concentrations in patients with benign breast disease rose 
over the three month period with the values for patients receiving AA 
rising more than the controls. At three months, the mean value in the 
patients with benign breast disease receiving AA was significantly higher 
(P< 0.01) than that in cancer patients who had also received the 
vitamin.
The individual values for the plasma and leucocyte AA concentrations for 
the cancer patients are shown in figures 16 and 17, respectively. When the 
values for the individual cancer patients were examined, it was found 
that both patients receiving AA and their controls fell into two groups 
depending on whether the values were higher on a subsequent visit. Mean 
values for each of the groups have been expressed as a percentage of the 
initial value and are shown in figure 18. This figure shows that for both 
treated and untreated patients, there were some who persistently showed a 
small decrease and others who showed a rise, particularly between the first 
and second visit. This figure again shows the difference in the effect of 
AA on plasma and leucocyte concentrations. The percentage of each kind of 
patient showing a value higher than the initial value at each subsequent 
visit is shown in Table 12. This table shows that the proportion of cancer 
patients showing a rise in AA concentrations was always higher in those 
receiving AA and that the proportion showing the rise was always higher for 
the plasma as compared with the leucocyte concentrations. These results 
are in contrast to those in patients with benign disease for both plasma 
and leucocyte concentrations rose in all patients receiving AA.
It might be suggested that some patients did not take the AA and that 
this would account for the lack of change in the blood values. Careful and 
judicious questioning in all cases included in these results elicited a
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Table 12 Percentage of patients showing rise in plasma 
and leucocyte AA concentrations after the initial 
sample was taken,
Plasma AA Leucocyte AA
— Visit s ,----Visit---
Early breast cancer 2 3 4 5 2 3 4
Controls 4l 48 65 40 43 55 47
Ascorbic acid 84 76 87 90 68 62 65
Benign breast disease
Controls ~ 66 ~ — ” 6 0 “'
Ascorbic acid 100
continuing assurance that the tablets were being consumed. In spite of this 
assurance, it seemed necessary to apply an easy objective test and it was 
hoped that the lingual vitamin C test (Cheraskin and Ringsdorf, 1968 a ) 
might be helpful. However, in our hands this proved totally unreliable as 
shown by a lack of correlations of the values with those from patients 
receiving the vitamin (figure 19).
Possible reasons in the cancer patients for the absence of a rise in 
leucocyte AA concentrations in spite of a rise in plasma concentrations 
seemed to be that other treatments received by the patients were in some 
way preventing entry of AA into the tissues, or that the renal threshold 
for AA was reduced in the cancer patients so that the vitamin was being 
more rapidly excreted, or that the vitamin was being more rapidly 
metabolised, possibly to oxalate.
3.2.1.1 Kinetic Study
The possibility that the vitamin was being rapidly excreted was examined 
in a kinetic study following a 3g loading dose. Urine samples were collected 
hourly for 7 hours.
The hourly excretion of AA by patients with breast cancer, patients 
with benign breast disease and age - matched controls is shown in figures 
20, 21 and 22, respectively. The total amount of AA excreted over the 7 
hour period was calculated for each patient and expressed as a percentage 
of the amount given (3g)» and mean values + S D are shown in Table 13. The 
proportion of the dose excreted by the cancer patients (7«j$) was 
significantly (P < 0.001) lower than that excreted by patients with benign 
disease (21.5%), or by the age - matched controls (16.6%). It.isto be 
noted that there was overlap in individual values for patients with benign 
disease with those for cancer patients (see figures 20 and 21). Thus, 
two of the patients with benign disease were excreting up to 43% of the 
dose, whereas the other three were excreting as little as 2.4%. However, 
it seems reasonable to conclude that the reason for the failure of the
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Table 13 Excretion of ascorbic acid following a loading dose of
3g by patients with breast cancer and benign breast disease 
and normal age - matched controls
Values are means + standard deviation for 5 subjects of 
each kind.
Breast cancer Benign disease Controls
Total excretion 7.5 + 1*2 21.5 + 8.6 16,6 + 1*9
% dose
Range of individual 3.1 - 10.1 
values
2.4 - 42.6 11.8 - 23.2
leucocyte AA concentrations of cancer patients to rise was not that the 
vitamin was being more rapidly excreted.
3.2.1.2 Urinary Excretion of Oxalate
The effect of ascorbic acid administration for three months on oxalate 
excretion was examined in the early morning samples brought to the clinic 
by the patients. There was no significant difference in the mean value 
for cancer patients who received AA (33*9mg/g creatinine) and cancer patients 
.not receiving the vitamin (25»7®g/g creatinine). Values for the two groups 
of benign patients (^1.6 and 4l.3mg/g creatinine, respectively) also showed 
no effect of AA administration on oxalate excretion.
3.2.1.3 Relationship of AA Concentration to Lymphocyte Response
The involvement of AA in immunocompetence has been discussed previously 
(§ 1.2.3.^) and tumourigenesis may be regarded as resulting from a defect in 
immunological surveillance mechanisms. Thus, it seemed possible that 
increased immunological activity in the cancer patients might account for 
increased utilisation of AA. In order to examine this possibility, patients 
with cancer were matched for age with patients with benign breast disease.
It was possible to obtain only six such pairs of patients, and the 
sequential leucocyte AA concentrations for these (Table 14) show no evidence 
of an association between response to AA administration and lymphocytic 
response in the tumour.
The majority of the cancer patients had undergone surgical removal of 
the primary tumour prior to entering the study, and thus, any increased 
requirement for AA must presumably be due to metabolic derangement resulting 
from removal of the tumour, later treatments or to metastatic disease. Rate 
of metastatic spread of tumours is related to degree of differentiation and 
to histological type. Comparisons with age - matched benign patients are 
shown in Tables 15 and 16, respectively. Again, the numbers are small so 
that no definite conclusions can be drawn. However, there seemed to be a
v —8Table 14 Leucocyte AA concentrations (ug 10” cells) in early breast 
cancer (EBC) compared with those in patients with benign 
breast disease (B) matched according to age
Patient Age Lymphocyte 
(yrs) response
AA Leucocyte AA concentrations 
|------- Visit-------- 1
EBG
B
EBC
E
EBG 
B .
EBG
B
EBG
B
EBG
B
66
64
48 
52
49
50
6l
65
63
64
40
39
Minimal
Minimal
Brisk
Brisk
-ve 13.1 7.3 16.4 32.9 26.8
-ve 6 A 34.6
+ve 33.O 27.3 8.8 26.3 21.9
*ve 30.7 - 35.7
Moderate -ve 12.6 36.8 17.5 58.4 24.0
-ve 13.3 14.4
Moderate +ve 20.0 35.4 31.3 19.7 40.1
+ve 14.3 40.4
-ve 17.6 10.1 16.6 18.6 21.1
-ve 6.4 34.6
+ve 29.9 36.7 19.9 23.6 21.4
+ve 9*8 54.5
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Table 16
Patient
EBG
B
EBG
B
EBG
B
EBG
B
EBG
B
EBC
B
EBG
B
EBG
B
EBG
B
EBG
B
—8Longitudinal leucocyte ascorbic acid levels (jig 10~ cells) for 
early breast cancer (EBC) patients whose primary tumour was 
histologically classified^ compared to age - matched benign (B) 
patients
VISIT
Age Tumour AA 1 2 3 4 5
Morphology
74 Lobular +ve 19.00 28.68 25.62 32.47 20.08
type
65 +ve 14.27 - ^0.63
58 Schirrous +ve 26.21 28.65 39*90 37*51 34.30
52 +ve 30.70 - 35*75
57 Schirrous -ve 9*20 10.00 16.21 20.79 14.38
Adenocarcinoma 
59 -ve 44.88 - 20.83
52 Adenocarcinoma +ve 6.72 29*11 22.79 27*56
52 +ve 30.70 - 35*75
55 Adenocarcinoma -ve 9.98 19.16 45.84 39*43 13*29
64 -ve 6.45 - 34.56
57 Anaplastic +ve 24.70 21.98 16.06 18.38 32.89
Carcinoma
52 +ve 30.70 - 35*75
64 Spheroidal +ve 15.01 66.98 23.15 15*94
Cell
65 Carcinoma +ve 14.27 - 40.43
68 Polygonal +ve 26.51 45.18 24.20 27.03 36.12
Cell
65 Type +ve 14.27 - 40.43
32 Intraduct +ve 17.26 15.07 19*55 33*99 34.50
32 +ve 8.9 - 55*74
48 Intraduct *ve 20.17 20.95 22.57 30.28
50 -ve 13.33 - 14.40
tendency for the leucocyte levels in cancer patients with poorly 
differentiated tumours to show no change with time, whereas those with 
better differentiated tumours tended to increase with time (Table 15).
There was no evidence of a link between the kind of tumour and the pattern 
of response (Table 16).
3.2.1.4 Side - effects of AA Administration
One possible metabolic side - effect of AA administration, namely, an 
effect on oxalate excretion has already been presented. A few patients 
reported other side - effects which were mostly the result of gastrointestinal 
disturbance. A summary of those reported is given in Table 17. It is of 
interest that symptoms in patients 1, 3 and 4 were associated with an 
allergic type of reaction.
3.2.2 Effects on the Urinary Excretion of Hydroxyproline (OHPro)
Early morning urine samples were analysed from 78 patients at presentation
with breast cancer. The mean OHPro s creatinine ratio in those with
identifiable, skeletal metastases was higher (4.4 + 2.8), than in those 
without metastases (1.7 + 1.8), or those with benign disease (1.3 + 0.7).
Ar total of 48 patients were classified on clinical grounds at presentation 
as having 'early breast cancer'. Of these, 7 patients, 5 of which were 
classified as and 2 as T-^ jj , Nq_-jMq had OHPro : creatine ratios > 2.
At mastectomy, 3 of these patients had lymph node involvement, 3 did not, 
and information was not available for the remaining patient.
The mean values for the OHPro s creatinine ratios of the patients
included in the ascorbic acid study are shown in Table 18. The mean values 
did not change significantly during the course of the study and mean values 
for patients given ascorbic acid did not differ from those of patients that 
did not receive the vitamin.
Sequential values for individual patients with metastatic bone disease 
are shown in Table 19. It is to be noted that although all these patients
Summary of Reported Side - Effects to the 
ingestion of 3g P©** day of AA
Table 17
Patient
1. Rectal bleeding
2. Flatulence
3* Nausea, vomiting and
loss of appetite
k. Stomach pains
5. Loose stools, diarrhoea 
and stomach pains
6. Skin irritation
7. Diarrhoea
8. Flatulence and loss
of appetite
Occurred after 6 months. Patient 
had history of citrus fruit 
intolerance.
Reported after taking AA for if years.
Reported immediately after 
starting regimen. Patient had a 
history of severe AA intolerance.
Reported after taking AA for one 
week. Eczema aggravated.
Reported two weeks after starting 
AA.
Reported after taking AA for six 
weeks.
Reported two hours after taking 3g 
loading dose during kinetic study. 
Symptoms severe and associated with 
migraine. Symptoms persisted for 
Zk hours.
Symptoms disappeared when dose was 
reduced to lg per day.
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had skeletal metastases, their OHPro ratio at presentation varied from 0.8
to 10.3, and at presentation, four patients had values < 2.0. Of the 13
patients given AA, 5 had died before the three month visit. All these patients 
!creatinine\
had OHPro^ratios >2 at presentation. A further patient died before the 5th 
visit and her OHPro ratio had fallen between visits 2 and 4 from 8.0 to 1.7*
i*
Five metastatic patients were not given AA and of these, two had died by 
visit 4 and one of these had an OHPro ratio < 2.
The disease in 12 of the patients initially diagnosed as being 'early 
breast cancer' was found to be progressive over the 12 month period of the 
study. The sequential OHPro ratios for these patients are shown in Table 20.
A total of 48 determinations was done on these patients and the OHPro 
ratio in only four samples was > 2. The highest value recorded was 8.1 in a 
patient with liver metastases who was treated with chemotherapy.
3.2.3 Plasma and Urinary Calcium and Phosphate
Plasma calcium and phosphate concentrations were measured at presentation 
in patients with early and metastatic breast cancer and in those with benign 
disease. There was no significant difference between the mean plasma calcium 
concentrations for those groups of patients (Table 21) and each of the means 
was within the normal range of 2.1 to 2.6 mmole dm . However, the range of 
values for patients with early breast cancer as well as that for metastatic 
disease shows that values for some individual patients exceeded the normal 
upper level.
Table 22 shows the proportion of patients in each group that initially 
exceeded the upper limit of the normal range for each determination. The 
urinary metabolites were expressed per urine volume for comparative purposes. 
Creatinine excretions were found to be consistent throughout the period of 
the study (t2=5«7mmole dm"^; Appendix 5). Values for the normal excretion of 
calcium and phosphate were calculated on the assumption that a normal 
urine volume is about 1.5 litres per 24 hours.
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Table 21
Plasma
Calcium
(mmole dm’
Plasma 
Phosphate 
(mg 100ml*"'
Urine
Calcium
(mmole dm
Phosphate 
(mg il~^)
Mean plasma and urinary concentrations of calcium and phosphate 
in cancer‘patients and in patients with benign disease 
(Values are means =tsp)' I
Cancer-
Metastatic Early Benign disease
Visit 1 Visit 1 Visit 3 Visit 1
No. 13 47 39 10
^)Mean 2.6 + 0.4 2.4 + 0.1 2.4 + 0.3 2.5 + 0.2
+ SD
Range 2.0 - 3.2 2.1 - 2.9 1.5 - 2.7 2.5 - 2.6
No. 13 54 - io
) Mean 3.2 + 0.9 3.4 + 0.8 - ' 3,7 + 0.9
± SD '
Range 2.2 + 4.6 3.1 - 4.9 - - 2.7 - 5,0
No. - 39 - 9
1.5 ± 1.1Mean - 2.6 + 2.4
+ SD
Range - 0.2 - 12.0 - 0.3 - 3.4
No. - 38 9
Mean - 4.2 + 2.2 - 2.4 + 1.5
± SD
Range - 1.2 - 10.8 - 0.5 - 5.7
Table 22 The percentage of patients in each group who initially 
showed calcium or phosphate levels above the upper 
limit of the normal range (shown in parentheses)
Metastatic
Patients
Plasma Calcium 46$
(2.1 - 2.6 mmole 
dm”3)
Plasma Inorganic 7$
Phosphate 
(3 - 100 ml”1)
Urinary Calcium 
(1.8 - 7.1 mmole 
dm"3)
Urinary Inorganic 
Phosphate 
(1.2 - 4.5mg ml”1)
Early Breast 
Cancer
6$
9f°
2$
42$
Benign Disease 
30$
20$
NONE
11$
Of the 47 patients with early disease whose plasma calcium was
measured at presentation, 39 patients were determined again three months
later. The mean value (2.38mmole dm” )^ was not significantly different
from that obtained on presentation (2.40mmole; dm~^). Of the patients
—3showing values of plasma calcium > 2.6mmole dm , one showed a sustained 
elevation whilst five showed isolated high values. Of these five patients, 
three were receiving AA during the period of study and one died during 
the study.
There were no differences in mean urinary calcium excretion between 
early breast cancer patients and those with benign disease. However, 
initial mean urinary phosphate excretion was significantly elevated 
(p = 0.02) in the cancer patients. This is reflected in the distribution 
of values in this group (Table 22).
Values for individual patients for plasma and leucocyte AA, urinary 
OHPro s creatinine and creatinine concentrations are shown in Appendices 
1» 2, 3» 4 and 5» respectively.
3.3 Discussion
3.3*1 Plasma and Leucocyte AA Concentrations
The mean initial plasma AA concentrations in the patients with benign
breast disease and those with early breast cancer were towards the upper
end of the usually quoted normal range for this measurement (0.6 - 1.2
mg 100 ml”1). Individual values were, however, scattered widely around
the mean, and 16 of the 51 patients available had values below 0*5 mg 100 ml
(see Appendix l). On the other hand , two of the cancer patients recorded
values of 2.6 and 4.2 mg 100 ml"1, respectively. The initial mean
concentration of leucocyte ascorbic acid in the cancer patients
—8w<& also within the normal range (24 + 4 ;ig 10 cells) with again a
wide scatter with values in the unsupplemented group having a range of 
o q
7.4 to 49.2 pg 10 cells and 6.7 to 34.4 ^ ig 10 cells in the supplemented
group. The initial mean leucocyte AA value in the patients with benign 
breast disease was significantly lower:;; than that in the cancer patients.
The majority of these patients were recruited into the study in the month 
of March and it could well be that this accounts for the low values. 
Griffiths et al. (1967) noted a seasonal variation in this measurement in 
their study of the elderly with the greatest number of patients with low 
values being admitted to their Unit in April. The vitamin G status of the 
new patients then increased throughout the summer until October when it 
again started to decline.
Plasma concentrations of AA reflect recent intake and therefore, as
expected, the mean values responded readily to supplementation in patients
with either cancer or benign disease (Table 11). The response to taking?
3g per day of AA was comparable with that found in two healthy males who
took 2.4g AA per day for 3 days (Harris et al., 1973)t 13 patients with
osteogenesis imperfecta who took 1 to 2g AA per day for varying periods
of time (Kurz and Eyring, 1974) and 10 patients with skin carcinoma who
took 6g AA per day for 7 days (Moriarty et al., 1978)* Kallner et al. (1977)
studied two individuals who initially received an AA restricted diet for
9 days. The plasma AA concentration rose from 0.43 to 1.07 mg 100 ml 1
-1and from 0.54 to 1.23 mg 100 ml respectively after the ingestion of 
l80mg AA daily for 2 weeks. This represented a mean rise of 0.7 mg 100 ml”1
compared with mean rises of 0.9 mg 100 ml”1 and 1.0 mg 100 ml”1 found in
/
our patients with breast cancer and benign disease respectively.
The changes in leucocyte AA following supplementation in patients 
with benign breast disease were similar to those found in previous studies 
of supplementation (Loh and Wilson, 1971a). However, the changes in the 
values in the patients with cancer were lower than those reported in 
normal individuals following varying periods of supplementation with 
200 to 1,500 mg/day (Brocklehurst et al., 1968; Loh and Wilson, 1971b). It 
therefore seems that in these patients there is a restriction of the
entry of AA into leucocytes since the concentration in the plasma rose 
in a manner similar to that of the control benign patients.
Some of the factors that might have been responsible for these 
differences have been examined.
3.3*1*1 Absorption
The mechanism by which AA is transfered across the intestinal wall is 
still not certain. In vitro and in vivo experiments in rats and guinea 
pigs suggest that both passive diffusion and a saturable component unit 
(Davis et al., 1977) exist. It appears that the latter process may be 
associated with sodium ions (Mellors et al., 1977)» and vary according to 
the region of the gut (iwamoto et al., 1975) and existing vitamin status 
(Odumosu and Wilson, 1978)*The absorption of AA in man has been studied by 
giving large doses of AA and following the ascorbate concentration in 
serum or plasma. Radioactive studies showed that up to a constant intake 
of l80mg of AA per day, 80% to 90% of doses of 30 to 60mg are absorbed 
(Kallner et al., 1977)• The efficiency of absorption is increased with 
increased frequency of ingestion of AA as the elevated ascorbate levels 
favour increased uptake by the tissues, but is decreased by increased 
losses via the urine. The decrease in efficiency of vitamin G absorption 
by the tissues with increased ingestion can be appreciated from Fig. 23 
(Lewin, 1976). From these extrapolations made by Lewin, it could be 
approximated that the individuals in our study could be absorbing about 
2g AA daily.
The possibility that neoplastic disease causes a change in absorptive
mechanisms has been investigated. The function of the small intestine
was studied in 26 patients with various malignant disease (Dymock et al.,
! one
1967). The ^patient with breast cancer showed a normal absorptive capacity. 
However, an abnormal jejunal structure was demonstrated in all 8 patients 
in whom a mucosal biopsy was studied. These and other observations led
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the authors to conclude that non - specific damage to intestinal function
may occur in malignant disease. AA was not studied. Furthermore, there
is no evidence of malabsorption of AA in patients with steatorrhoea
(Stewart and Booth, 196^ ). Furthermore, Kakar (1978) found no difference
in the increments in plasma and leucocyte AA concentrations in leukaemic 
|control
children and/^ university students following oral doses of the vitamin. The 
increase in plasma AA levels seen in the early breast cancer patients 
taking the vitamin further suggests that failure in absorption is not the 
major factor explaining the restricted leucocyte AA values in these 
patients.
3.3*1*2 Radiotherapy
Radiotherapy (RT) could further affect AA status. However, in the
present study, the unsupplemented patients showed no appreciable difference
in either mean plasma AA or leucocyte AA levels following RT, that is at
the second visit. Kakar et al. (1977) did find a significant rise in LAA
in 10 assorted cancer patients after radiotherapy which could be
attributed to the marked fall in total white blood cell (WBC) count.
Similar non significant reductions in total WBC counts were found in
postoperative mammary carcinoma patients after RT (Stjemswald et al.,
1972). Loh and Wilson (1971c) demonstrated a significant negative
correlation between the total WBC count and leucocyte AA in young healthy
adults indicating that a rise in total WBC count is normally associated
with a fall in leucocyte AA concentration and vice versa. In an attempt
to eliminate this effect, the results of our study were calculated in
terms of mg 100 ml blood. The pattern of leucocyte changes, however,
remained the same, and it was decided to express the results in terms of
—8total concentration 10~ cells, so that the results could be compared 
directly with those already published. Although quantitative changes 
following RT were small, qualitative differences were found, in that most 
of the patients taking vitamin C experienced faster healing of X ray
damaged tissue. Unfortunately, no objective measurements were made of 
this effect.
3.3*1*3 Drugs
Drugs taken could affect the AA status for a number of drugs lower 
the concentration of AA in the blood. Clinical scurvy has been described 
in a patient with rheumatoid arthritis treated with prednisone (Bartholomew, 
1972) and high doses of aspirin, also used in the treatment of this 
condition, deplete the tissues of this vitamin (Sahud and Cohen, 1971). 
Others have shown that aspirin prevents ascorbic acid entering the 
leucocytes((Loh et al., 1973)*
However, the drug intake in the early breast cancer patients was 
minimal as they were studied before and after prophylactic RT and therefore 
many were technically 'disease free'. It would seem therefore that the 
effect of medication on the average leucocyte AA levels would be negligible.
3.3*1*^ Uptake of Ascorbic Acid (AA) into the Leucocytes
Differences between the timing of increases in the concentrations of 
AA in the plasma and leucocytes of the patients with benign disease and 
those with cancer suggest that entry into leucocytesiin the cancer patients 
may well have been limited. In vitro studies have led to the conclusion 
that AA transport into leucocytes occurs by both passive diffusion and 
active transport (Loh and Wilson, 1970a). Moreover, this transport system 
is affected by the presence of aspirin (Loh et al., 1973) and ferrous iron 
(Loh and Wilson, 1970b). Practically all the AA in the plasma and 
leucocytes is in the reduced state, whereas it occurs in the erythrocytes 
almost completely as dehydro AA. Leucocytes do not absorb dehydro AA to 
any significant extent, but incubation of erythrocytes in dehydro AA leads 
to a significant increase in the concentration of AA in the supernatant 
fluid. Furthermore, simultaneous incubation of erythrocytes with 
leucocytes in dehydro AA results in a significant increase in the AA
concentration in the leucocytes (Loh and Wilson, 1970a). A mechanism
hoexists to enable leucocytes^actively absorb AA, which originates from 
the dyhydro AA taken up from the plasma by the erythrocytes, and this 
is ferrous mediated.
It has been shown that the reversible flow of AA between the plasma 
and leucocytes is partly governed by factors in the plasma.(Mohanram and 
Srikantia, 1967) which it could be postulated are altered under cancerous 
conditions. However, an in vitro study showed that the AA content of 
leucocytes from 6 leukaemic children were significantly higher after 
incubation with AA (Kakar, 1978)* Yet Basu et al.,(1977) demonstrated 
that the amount of AA uptake by leukaemic leucocytes was lower than that 
of normal controls. AA shows considerable lability in its passage in and 
out of the plasma under normal physiological conditions. These fluctuations 
undergo a regular 24 hour circadian rhythm during which maximum amplitudes 
occur at 11.58 am and 10.35 am in leucocyte and plasma respectively 
(Wilson and Loh, 1969). AA status is also affected by sex, cigarette - 
smoking and age (Brook and Grimshaw, 1968).
Further investigation of the effect of various types of cancer on 
the uptake of AA into leucocytes is necessary and such studies could well 
throw some light on the entry of AA into other cells, for leucocyte AA 
is generally considered to reflect cellular AA.
It seemed possible that the restriction in leucocyte response to 
supplementation could reflect a difference in metabolism and utilization, 
and therefore excretion of the vitamin in these early breast cancer 
patients.
3.3*2 Kinetic Studies
The two important issues arising from the kinetic study results are,
a)the differing pattern in AA excretion following the ingestion of a 3g 
dose of the vitamin in the three groups (Figs. 20, 21 and 22), and
b) the overall apparent retention of the vitamin in the breast cancer 
group (Table 13).
The excretory profiles for the cancer patients are all compact, 
whereas those of the benign patients appear to be almost biphasic in 
nature. Two patients excreted much greater concentrations of the vitamin 
than the remaining three, who showed similar profiles to those of the 
neoplastic group. It could be postulated that these three benign patients 
had a disposition towards neoplastic change. If this were so, it could 
have diagnostic implications. In contrast, the individual profile of each 
normal control appears to differ, and this fact has been reported.previously 
(Booth and Todd, 1970). Furthermore, Todhunter and Robbins (1940) found 
a great variation of urinary output per 24 hours between normal individuals 
ingesting the same amount of the vitamin. A retention of AA in malignant 
disease has been reported by others (Minor and Ramirez, 1943; Kakar, 1978). 
However, the degree of tissue retention of AA will to a certain extent 
depend on existing reserves of the vitamin (Kyhos et al.V l^^'ii’T^^isfJPssible 
that the results of these previous studies are merely a reflection of the 
general anorexia known to be associated with the disease itself (DeWys,
1979). All the patients, both those with cancer as well as those with 
benign disease, in our study, were outpatients, attending routine follow - 
up appointments and thus could be assumed to have previously received 
normal intakes of the vitamin.
The excretion of AA in women fluctuates during the menstrual cycle 
(Loh and Wilson, 1971d). Two of our normal controls (BW and JW) and one 
benign patient (SS) were premenopausal. With such a small number of 
patients in each group, it is impossible to identify any hormonal effect.
It is evident that the large variation in early urinary losses seen in 
some of the premenopausal women are observed in many of their post - 
menopausal counterparts.
Several factors must be taken into account when comparing studies of 
supplementation. These include variation from subject to subject, and 
even within the same subject, and also the mode of administration of 
the vitamin. Intravenous injection eliminates the gut barrier, and in the 
gut the presence of chelating agents and oxidative conditions could affect 
the biological activity of the vitamin administered. In the gut, 
absorption of the vitamin is also influenced by the conditions as well as 
by the timing of oral ingestion. In the present study the conditions were 
carefully controlled in: each set of patients in order to reduce the 
number of variables between groups.
Consideration of these matters suggests that the restriction in the 
rise in leucocyte AA concentrations following supplementation could be 
a reflection of a widespread change in the general metabolism and 
utilisation of the vitamin in early malignant disease.
3.3*3 Urinary Excretion of Oxalate
The mean oxalate excretions were similar in early breast cancer 
and benign patients (46.8 mg/g creatinine and 4l.4 mg/g creatinine 
respectively). Furthermore, it appears that AA ingestion had little effect 
on the mean oxalate excretion in both sets of patients. However, the 
excretion of this metabolite was high in two individuals in the supplemented 
cancerous group (73 and 182 mg/g creatinine) and a further two supplemented 
benign patients were excreting 60 mg/g creatinine. In these latter patients, 
the high excretion may simply represent their normal level and not a 
response to ascorbic acid ingestion. This is supported by the fact that a 
few unsupplemented patients excreted oxalate in concentrations approaching 
the upper limit of the normal range. The normal oxalate excretion is 
approximately 10 to 25 mg/g creatinine, assuming that 2g creatinine is 
excreted per day. In primary oxaluria, an excretion of 50 to 200 mg/g 
creatinine occurs (Atkins et aX.,1963).
The findings in the present study are in agreement with those of 
Lamden and Chrystowski (1954) and JTakenouchi et al. (1966) who suggested 
that doses up to 3g AA did not increase oxalate excretion.
3.3*4 Neoplastic Effects
From the foregoing discussion, it is tempting to suggest that the 
early breast cancer patients as a group had an increased requirement for 
the vitamin. Evidence of depleted AA levels in cancer patients compared 
to normal controls (Krasner and Dymock, 1974), preferential accumulation 
in neoplastic tissue (Kakar and Wilson, 1976) and suggested accelerated 
usage of the vitamin by carcinomatous tissue (Minor and Ramirez, 1943), 
appear to support this hypothesis. The question as to whether specific 
tumour characteristics, such as the degree of differentiation or 
histological type or the host's immunological reaction to neoplastic 
invasion, further affect the ascorbic acid utilisation, unfortunately 
could not be answered in this study. However, the individual trends which 
were highlighted in section 3.2.1.3 are of interest. Clearly, more work 
needs to be carried out in this area.
3.3.5 Urinary Excretion of Hydroxyproline (OHPro)
The high excretion of OHPro found in the metastatic patients has been 
encountered by others (Bonadonna et al., 1966; Cuschieri and Felgate, 1972). 
Urine samples collected under the same conditions from metastatic patients 
by Powles et al. (1976) yielded marginally higher mean values of 7.0 + 3.6. 
Indeed, as observed by Coombes et al. (1977) approximately 75% of the 
patients with identifiable osseous deposits exhibited elevated OHPro : 
creatinine ratios. The high mortality rate in Coombes' patients 
highlights the possible prognostic value of this determination (Cuschieri, 
1975» Powles et al., 1975)*
The diagnostic implications of urinary hydroxyproline have been 
discussed previously (g 1.2.2). This thesis provides little further
evidence regarding this. Possibly the early breast cancer patients were 
not studied for a long enough time after mastectomy, and the disease - 
free period extended over and above the period of study. However, it is 
interesting to note that two patients with liver recurrence exhibited 
early elevations in hydroxyproline/creatinine excretion. Cuschieri and 
Felgate (1972) found that hydroxyproline excretion was raised in advanced 
cancer patients with either osseous deposits or soft tissue metastases. 
However, the OHPro s creatinine ratio was significantly elevated only in 
cases with skeletal deposits.
Ascorbic acid ingestion appeared to have little effect on the OHPro : 
creatinine ratio in any group of patients. Basu et al. (1974b) observed 
a fall in OHPro excretion in patients with skeletal metastases , 4 to 12 
hours after the administration of lg AA. The difference between Basu's 
findings and those of the present study could be due to the fact that 
Basu et al made their observations over only a short period. It is of 
interest in this connection that other short term changes in bone metabolism 
have been reported to occur in chicks following AA supplementation 
(Thornton, 1968). In addition, the metastatic patients in this study were, 
in the main, hormonally controlled by drugs such as tamoxifen which is 
associated with oestrogen blocking mechanisms. Hormones of ovarian 
origin decrease urinary CHPro (Katz and Kappas, 1968; Heller et al., 1979). 
This treatment could well obscure any depressing effect which might be 
brought about by vitamin G ingestion.
3*3*6 Plasma and Urinary Calcium and Phosphate
The mean levels of plasma calcium and phosphate showed little difference 
between the three groups of patients. This was at first surprising since 
there are numerous reports of hypercalcaemia associated with advanced 
mammary carcinoma (Galasko and Bum, 1971)* The distribution of these 
advanced cancer patients probably reveals more. Approximately half the 
metastatic patients exhibited plasma calcium concentrations greater than
the-upper normallimit (Table 21). Previously cited incidence rates of 
hypercalcaemia with metastatic disease range from 8 - 9^  (Woodard, 19531* 
14$ (Swyer et al., 1950)1 and 42^ (Thomas et al., i960). The aetiology 
of this hypercalcaemia has been discussed (§ 1.2.1). Calcium is 
constantly entering the plasma from bone and gut and leaving for bone or 
urine and consequently its circulating level is affected by endogenous 
factors such as absorption and clearance rates and exogenous factors 
including hormone ingestion (Herrmann et al., 1949). Bearing in mind the 
dynamic nature of circulating calcium, it is questionable whether random 
sampling would highlight the finer points of mineral exchange during 
metastatic disease which have subsequently been revealed by carefully 
controlled balance studies (Coombes et al., 1976). Clearly, more work 
needs to be carried out in this area.
The high urinary phosphate output observed in the early breast cancer 
group may have diagnostic implications. High phosphate loss has been 
observed in metastatic osteolysis following breast cancer (Laszlo et al., 
1952). However, the degree of significance seen in this study was not 
great, and considering the many factors which may contribute to phosphate 
concentrations in urine, the findings could quite conceivably have other 
causes. Concentrated sequential determinations of urinary phosphate in 
early breast cancer patients at differing times following mastectomy need to 
be carried out in order to clarify this point.
CHAPTER FOUR
4. TRYPTOPHAN METABOLISM
4.1 Introduction
Literature relating to the abnormalities of tryptophan metabolism 
that have been described in patients with breast cancer has been 
reviewed in Chapter 1 (§ section 1.2.4).
Plasma concentrations of tryptophan were measured in patients with 
early breast cancer and in patients with benign breast disease. The 
concentration of tryptophan metabolites in the urine was also measured 
in the early morning urine sample which was obtained for the measurement 
of hydroxyproline excretion. Since no difference was noted in any of these
parameters between patients receiving ascorbic acid and those not receiving
the vitamin the values presented are the means for all patients.
4.2 Results
4.2.1 Plasma Total Tryptophan Concentrations
Table 23 shows the mean total tryptophan (pg ml” )^ in the plasma of
patients with breast cancer compared with those of patients with benign 
disease. The sequential determinations for the benign patients were 
directly compared with those at visit 3 of the cancer patients since the 
time between sampling was 3 months in both cases. The mean circulating 
level of tryptophan was significantly lower in the cancer patients both 
initially (p < 0.001) and on the subsequent occasions (p < 0.001). 
Furthermore, the small standard deviation (SD) observed in this group 
indicated that there was a small individual variation and that consistently 
lower plasma total tryptophan levels were encountered in virtually all 
the patients studied.
Amongst the cancer patients further statistical analysis showed that 
patients who presented with disseminated disease (lymph node +ve) had 
similar values to those with no proven metastatic disease (lymph node -ve).
By the time that the cancer patients made their fourth visit the plasma 
tryptophan concentrations of some of them had risen to values that were
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within the range of those found in the patients with benign disease. Thus,
on the first visit 73% of the cancer patients had values that were less
-1 —1than lOpg ml whereas at the fifth visit 51% had values less than lOpg ml .
The plasma tryptophan concentrations in both groups of patients were 
analysed with respect to menopausal status on the assumption that 
patients over the age of 50 years would be postmenopausal. Cancer patients 
below 50 years of age on the first visit had significantly higher plasma 
tryptophan concentrations (10.7 5 ^  ml”1 + 2.91) than the oldest, 
presumably postmenopausal patients (8.67pg ml + 2.39» p<0.05). A 
similar difference in the mean values of patients in the two age groups 
was also found on the initial visit in patients with benign disease.
Patients in the younger group had a mean value of 13.4l;ig ml*"1 + 2.9 and 
those in the older group had a mean value of 10.31pg ml”1 + 1.28, p < 0.05. 
When the values for all the patients, i.e. those vrithcahcer and those 
with benign disease were pooled, the age effect was exaggerated for the 
mean value in the younger patients was 12.0pg ml""1 + 2.96 compared with 
8.8Tpg ml”1 + 2.42, and the difference was highly significant (p < 0.001).
4.2.2 Urinary Excretion of Tryptophan Metabolites
Urines from the first visit were analysed. Table 24 shows the mean 
concentrations of three metabolites - xanthurenic acid (XA), 
N-methylnicotinamide (NMN) and 5-hydroxyindolacetic acid (5-HIAA) in the 
urines of both groups of patients and Table 25 shows the mean values 
expressed as mg g creatinine 1. Both groups of patients excreted similar 
mean amounts of 5-HIAA and although the concentration of XA was higher in 
the urine of patients with cancer than in that of patients with benign 
disease, the difference was not statistically significant and disappeared 
when the values were related to creatinine. There was, however, a highly 
significant difference in mean values for the excretion of NMN between the 
two groups (p < 0.001) and this was exaggerated when the values were related 
to creatinine.
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4.3 Discussion
The concentration of tryptophan in the plasma is the result of the 
interplay of a number of processes. Thus, it is affected by the amount and 
nature of the protein in the diet, the absorption of the amino acid from 
the small intestine, by the anabolism and catabolism of protein and by the 
activity of the xanthurenic acid and serotonin pathways of metabolism.
In general, foods of animal origin are richer sources of tryptophan 
than those of plant origin (Krause and Hunscher, 1972) and therefore it 
would be expected that vegetarians, and particularly vegans, would have 
lower concentrations of tryptophan in their plasma than omnivores.
Although the patients were not specifically asked about their diets, it 
is very unlikely that the lower mean tryptophan concentrations in the 
cancer patients was due to more of them consuming a vegetarian diet.
Abnormalities of intestinal absorption have been reported in patients 
with cancer (Dymock et al., 1967). These observations were in agreement 
with an earlier report (Creamer, 1964) in which six of the nine patients 
studied had abnormalities of the jejunal and ileal mucosa. In only two of 
Creamer's cases was the primary lesion within the alimentary tract. The 
remaining four patients with abnormal mucosal histology had tumours of the 
bronchus, adrenal, cervix and ovary. Both these studies included only one 
case of breast cancer and this patient of Dymock*s had no evidence of an 
abnormality of absorption. Neither of these reports included adequate 
characterisation of the patients with respect to stage of the disease and 
the presence of metastases for it to be possible to assess whether the 
abnormalities described were, in fact, the direct result of the tumour 
or the result of chronic illness with concomitant malnutrition. It would 
seem that a failure to absorb tryptophan from the intestine was an unlikely 
cause of the low plasma concentrations.
Tryptophan is the only amino acid which is bound to an appreciable
extent to plasma albumin. No attempt was made in this study to determine 
the 'free' and 'bound' fractions of tryptophan since heparinised blood 
is unsuitable for this fractionation (Fernstrom, 1979)* The concentration 
of 'total* tryptophan might be reduced if the plasma albumin concentration 
was reduced. However, there was no evidence that the albumin levels of 
the cancer patients were consistently lower than those of controls. Neither 
would it seem possible that they were low because of removal for 
incorporation into tumour proteins since none of the patients studied had 
at this time any evidence of metastases. Tryptophan does, however, play a 
key role in the regulation of hepatic protein metabolism and specifically 
in the maintenance of aggregated polysomes (Staehelin et al., 1967). It 
also performs a similar function in the brain (Aoki and Siegel, 1970).
From the mean values presented in Tables 23 and 24 it would appear 
that the low levels of plasma tryptophan encountered in the early breast 
cancer patients were associated with an elevated excretion of the tryptophan 
metabolite, NMN. However, when all the individual values for these patients 
were compared statistically using linear regression analysis no significant 
negative correlation was found, due presumably to a wide individual variation. 
This does not, however, indicate that no negative correlation existed, 
but simply that it was not linear. However, the majority of the individual 
patients (32 from 58) did have values for those parameters suggestive 
of a negative correlation and it may be that a curvilinear relationship 
exists. It is therefore possible that in some patients the low plasma 
levels are the result of stimulation of the xanthurenic acid pathway of 
tryptophan metabolism which in adequately nourished individuals terminates 
with the excretion of NMN. Two related facts about this pathway are 
relevant to the present discussion. These are that a number of enzym'es 
involved in this pathway require pyridoxine, vitamin B^ , as a co-factor 
and that the rate-limiting enzyme in the pathway, tryptophan pyrrolase, is 
induced by adreno-corticosteroids.
The adminstration of oestrogen-containing oral contraceptive agents 
to some women results in clinical symptoms - nausea, lassitude and 
headaches, which are relieved by vitamin (Adams et al., 1973)* Indeed, 
if a 2g tryptophan load is administered to such women it is found that 
they excrete greater than normal amounts of xanthurenic acid and this is 
taken as evidence of pyridoxine deficiency (Price et al., 1967). We did 
not give a tryptophan load to our patients but they were generally 
excreting amounts of xanthurenic acid which were similar to those of the 
control patients with benign disease. It is therefore reasonable to 
conclude that there was no evidence of pyridoxine deficiency in the 
majority of our cancer patients.
The lower mean age of the benign group (46 years range 32-65) compared 
to the early breast cancer group (59 years range 32-78) could contribute 
to the difference in plasma total tryptophan between these groups. Indeed 
age differences in tryptophan metabolism do exist (Rose and Randall,
1973a) and postmenopausal levels of plasma total tryptophan were found to 
be lower in this study. However, the age effect is smaller than the 
cancerous effect, as seen by the smaller degree of significance between 
the mean tryptophan levels of pre and postmenopausal patients within each 
group compared to that of benign and early breast cancer patients.
There is now extensive literature on the hormonal change in patients 
with breast cancer and it seems that hormones may play a role in both 
the aetiology (Bulbrook, 1972) and promotion (Adams et al., 1979) of 
breast tumours. Oophorectomy, sometimes with adrenalectomy and 
hypophysectomy, is used in the management of patients with breast cancer.
In rats, oophorectomy causes a decrease in the excretion of NMN which 
increases again when the hormonal status was restored (Lojkin, 1956).
The rate-limiting enzyme in the pathway of metabolism to NMN is the hepatic 
enzyme tryptophan pyrrolase. Induction of this enzyme by oestrogen, via 
an effect on the secretion of adrenocorticosteroids is responsible for the
increased metabolism of tryptophan down this pathway in oral contraceptive 
agent users. It therefore seems possible to suggest that hormonal 
stimulation of tryptophan pyrrolase in the presence of adequate 
pyridoxines is the cause of the elevated excretion of NMN in some early 
breast cancer patients. Induction of tryptophan pyrrolase may also occur 
as the result of the effects of psychological and physical stress on the 
production of adrenocorticosteroids (Altman and Greengard, 1966). It 
could well be that such an effect would diminish with time and such a 
change might explain the gradual increase with time in the plasma 
tryptophan levels of the cancer patient. This increase in tryptophan levels 
could also represent a trend towards normal metabolism brought about by 
the beneficial effects of treatment mediated by balanced endocrine 
activity. Rose and Randall (1973&), in a related study, concluded that there 
was an average fall in tryptophan metabolite excretion in early breast 
cancer patients, many of whom were premenopausal at the start of the 
study, during a 5 year period. However, there is also a reduction in 
tryptophan metabolite excretion in normal women with increasing age. 
Furthermore Rose and Randall (1973a) showed that diminished excretion of 
metabolites occur in some women with breast cancer treated with oophorectomy. 
Mastectomy itself produces a marked and prolonged change in urinary 
steroid excretions (Bulbrook et al., 1967) which could reflect altered 
hormone activity, and these effects may have been operative in our study 
when some of the initial blood samples were taken but subsided during the 
subsequent months.
Differences in the values found for plasma total tryptophan in the pre 
and postmenopausal early breast cancer patients were not reflected in the 
values obtained for the three urinary metabolites studied. Price et al.
(1967) suggest that a loading dose of tryptophan may be required to 
accentuate changes in urinary metabolite excretion brought about by 
altered hormonal status. This oestrogenic effect may be due to a possible
protective action that this hormone has on the circulating amino acid, 
exerting a blocking mechanism on its degradation. Indeed it has been 
demonstrated that sulphate esters of oestrogenic substances exert an 
intense inhibitory action on the kynurenine transaminase of rat kidney 
by competing with pyridoxal phosphate for the apoenzyme (Mason and 
Gullekson, i960). Later, Wynick and Bender (1981) showed that oestrone 
glueuronide, the principle human metabolite of oestrone inhibited 
kynureninase, another pyridoxine dependent enzyme. Thus, if a tryptophan 
load was given the excretion of 3"hydroxykynurenine and xanthurenic acid 
would increase, and pyridoxine would be expected to reverse this inhibition.
A number of studies of tryptophan metabolites have been made with 
breast cancer patients, usually involving loading doses of the amino 
acid and collection of 24 hour urine samples. Since, in this study the 
women were outpatients urine collection over 24 hours was not feasible. 
Consequently, values for tryptophan metabolites were expressed on a 
creatinine basis. Creatinine is normally accepted as being constant in 
its excretion. Thus, comparison with other studies is not facilitated. 
Nonetheless, Basu et al. (1973) using a similar approach to this study 
found a very different trend. The mean urinary 5HIAA level in assorted 
advanced cancer patients (l3.9mg/g creatinine) was above both sets of 
controls (2.2, 2.7mg/g creatinine). Conversely, urinary excretory levels of 
NMN in the cancer patients was markedly decreased (2.7mg/g creatinine) 
compared with those of the controls (9.0, 8.1mg/g creatinine). Delange 
and Joubert (1964) found a mean value for NMN of 4.3mg/g creatinine in 
healthy controls, which is comparable with that found in the benign group 
of this study. The majority of other studies involved the collection of 
24 hour urine samples and concentrated on the urinary excretion of 
xanthurenic acid and other metabolites of the kynurenine pathway of 
degradation (§ section 1.2.4). The results of these previous studies are 
conflicting, both in the cancer and control groups making further evaluation 
of them of little value.
In view of the complexity of the metabolic pathways available to 
tryptophan it is not remarkable that abnormalities in its metabolism have 
been observed and there are a number of clinical conditions in which 
disorder of the tryptophan-niacin pathway is frequently observed (Price, 
1958)* Such disorders may be induced by drugs or certain nutritional 
deficiencies. There are, however, a few examples of hereditary abnormalities 
of tryptophan metabolism. In such a situation as seen in the early 
breast cancer patients where increased quantities of tryptophan are being 
catabolised along the tryptophan-niacin pathway, the availability of the 
amino acid is of prime importance. This may be optimised by a combination 
of an adequate diet, efficient absorption leading to sufficient quantities 
of the circulating amino acid available for increased nicotinamide 
synthesis, serotonin formation and protein synthesis. Indeed, Reynolds,
(1957) pointed out that the average daily intake of tryptophan by 
Americans is about 0.9g, while the minimum daily requirement for women is 
about 0.l6g and for men, 0.25g. Therefore, a considerable quantity of 
dietary tryptophan could be available for conversion to catabolic 
products such as NMN. A further metabolic consequence caused by the increased 
activity of catabolising enzymes such as kynureninase could be the relative 
deficiency in the pyridoxine cofactor. This was not evident in the 
majority of our patients, or in other baseline studies involving breast 
cancer patients (DeGeorge and Brown, 1970? Davis et al., 1973)• Tryptophan 
loading may be needed to demonstrate this deficiency (DeGeorge and 
Brown, 1970)*
CHAPTER FIVE
5. METABOLIC PROFILES
5.1 Skeletal Metastases in Early Breast Cancer Patients
Many workers have tried to develop biochemical procedues of sufficient 
sophistication and simplicity so that they may be applied to the many 
problems of breast cancer. Primarily a test is needed to identify women 
with a substantially increased risk of developing the disease and a test 
which would detect breast cancer before it has reached sufficient size 
to be detectable by any presently available means. Finally biochemical 
measurements applicable to either the patient or tumour are needed to 
indicate the prognosis of the patient and supply information that may be 
useful as a major determinant in the decision as to the type and vigour 
of the therapy for a specific patient.
Whatever predictive tests may be contemplated it is essential that 
complete pathological data are also available. The differences between the 
recurrence and survival experience of women in various well defined 
clinicopathological catagories is so great that it would be pointless to 
expect biochemical tests to override them (Bulbrook, 1976). The value 
of such tests lies within these clinicopathological classes, for example 
80% of women with four or more axillary nodes involved will have a 
recurrence within five years of mastectomy, but the disease - free interval 
for the remainder may be longer than this.
It has been claimed that measurements of the tumour cell labelling 
index, tumour enzymes and hormone receptor proteins are useful for 
prognosis. So far as the host is concerned, plasma and urinary androgen 
levels, tumour index substances, methylated breakdown products of RNA, 
hydroxyproline, tryptophan metabolites and various measurements of 
immunochemical function are reported to correlate with recurrence rates. 
However, in the opinion of many authorities none of these tests is of 
sufficiently proven reliability for the day to day management of patients 
with breast cancer (Bulbrook, 1976).
During the period of study (March 1978 - October I98O) 5 of the
early breast cancer patients showed clinical signs of skeletal involvement
which were confirmed by positive bone scans. Two of these patients were
under *K) years of age and 4 died during the period of study. Table 26
shows the available clinical data for these patients. Four of the five
patients had involvement of the lymph nodes at presentation and this was
confirmed in three of them at surgery (the fourth patient underwent
surgical removal of the primary lesion without dissection of any lymph
nodes). The primary lesions were described as poorly differentiated in
four of the five patients. All the tumours had infiltrating characteristics.
These factors contribute to the later appearance of skeletal metastases
(see section 1.3)* Originally three of these patients were receiving
vitamin G (3? daily}-following their entrance into the study, however one 
|(table 27)
patient (A.P.^reported severe intolerance of the vitamin in this dosage 
and stopped taking it after 6 weeks. It was possible to collect blood 
and urine samples after proven skeletal involvement from four of the 
patients and the available data from each patient are individually 
presented in Tables 27, 28, 29, 30 and Jl. The disease free period varied 
from 5 to 12 months with an average of approximately 8 months. All these 
patients complained of pain prior totthe skeletal scans. Bone and liver 
scans were routinely carried out on presentation and annually following 
surgery.
The large individual variation in ascorbic acid levels discussed in
Chapter 3 (section 3»l) is again reflected in this small group of
I(table 30) ,
patients. For instance E.T./v, showed a marked desaturation with respect to 
the vitamin prior to death when leucocyte levels fell to a low level of
O
9.^ pg 10 cells accompanied by a similar depleted plasma ascorbic acid
t (table 31)
concentration (0.6mg 100ml" ). M.Wyvshowed a marked fall in plasma ascorbic 
acid concentrations following skeletal involvement. However, the 
leucocyte concentrations which Jiad previously slowly risen in response to
(table 27)
supplementation did not fall. A.P.^showed a steady decline in leucocyte
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ascorbic acid values before skeletal involvement was diagnosed and no
' (table^28)
change was observed after the bone scan. One patient (D.T.),^ however, 
showed marked physiological desaturation of the vitamin following 
evidence of bone involvement. This was observed both in plasma and 
leucocyte ascorbic acid levels.
JThe rise in urinary hydroxyproline/creatinine ratio in one patient 
Li table 50)
(E.T.)/ypredated both clinical manifestation of pain and radiological
confirmation of the presence of bone metastases. This patient also had
the shortest disease free interval (5 months) and it might be anticipated
that a similar change would be found in the other patients if observed
;(table 28)
at the same time before skeletal recurrence. However, D.T.y^ showed no 
elevation in this measurement 6 months before positive evidence of 
skeletal involvement. The ratio was raised in two out of three of these 
patients after the bone scan had reported to be positive. The period of 
time by which elevated urinary hydroxyproline/creatinine ratios may 
precede the development of clinical and roentogendlogical evidence of 
bony metastases has been seriously claimed to vary from 1 -77 months 
(Guzzo, 1969)$ 2 years (Cuschieri and Felgate, 1972), several months 
(Cuschieri, 1973) and 3 months (Coombes, 1979)•
The inverse relationship between urinary hydroxyproline/creatinine
ratios and leucocyte ascorbic acid concentrations previously observed
in advanced cancer patients (Basu et al., 197^) was observed in two of 
;(table 30)
these patients. E.T.^showed successive tissue desaturation in ascorbic
acid and concomitant increase in hydroxyproline excretion prior to
bone involvement. Similarly the low, post - bone scan ascorbic acid levels 
(table 28)
seen in D.T./\were accompanied by abnormal urinary hydroxyproline/creatinine 
ratios. However, Bates (1977) failed to show any significant correlation 
between plasma or buffy coat vitamin G and total urinary hydroxyproline 
whether expressed on a creatinine basis or on total amino acid basis in 
23 healthy elderly subjects. It could be postulated that such a
relationship only becomes apparent in extreme cases of vitamin depletion 
for Windsor and Williams (1970) demonstrated a response in the 
excretion of hydroxyproline in relation to creatinine in scorbutic 
patients which did not occur in healthier individuals. The biochemical 
interrelationship between these two measurements has been discussed in 
Chapter 1 (see section 1.2.2).
Plasma calcium concentrations were elevated in only one patient prior 
to the confirmation of skeletal metastases and even after the presence of 
metastases was confirmed the frequency of hypercalcaemia was low. Two 
patients showed a steady rise in total alkaline phosphatase at visits 3 
and and these remained high following evidence of skeletal involvement. 
Elevated alkaline phosphatase levels were accompanied either by normal 
plasma calcium levels or those suggestive of slight hypercalcaemia, but 
were always accompanied by a high urinary hydroxyproline/creatinine ratio. 
However, serum alkaline phosphatase activities are always difficult to 
interpret in patients with widespread neoplasia because of the possibility 
of liver metastases and the non specific nature of this determination 
in the absence of the separation of its isoenzymes.has been pointed out 
(Nordentoft, 1965). Where isoenzyme determinations were carried out the 
results have been indicated on the tables.
Basu et al. (I97^ c) failed to demonstrate any correlation between 
plasma alkaline phosphatase activity, the calcium levels or the extent 
of skeletal metastases. Previously, Mir^jouska et al. (1968) concluded that 
hydroxyprolinuria appeared to be generally more reliable than either 
alkaline phosphatase or calcium determinations when bone spread of a 
tumour was suspected. The relationship between hydroxyproline excretion 
and calcium metabolism in cancer was studied by Klein et al. (196^) who 
found that in six patients with metastatic bone disease an increase was 
usually associated with a high rate of calcium resorption. Their studies 
were undertaken with the aid of radioactive calcium (^Ca) for kinetic
analyses, but unfortunately data on serum and urinary calcium were not 
reported. It is evident from the data of Bonadonna et al. (1966) that 
in individual cases urinary hydroxyproline may be considerably elevated 
despite normocalcaemia and normocalci uria but the reverse is not true.
In every case of hypercalci uria reported by the authors the urinary 
hydroxyproline was elevated and in all except three cases of 
hypercalcaemia it was likewise elevated. Thus, the authors suggested that 
an increase in urinary hydroxyproline may accompany an increased 
resorption rate of calcium but that it may in addition, reflect changes, 
independent of calcium metabolism. In addition, of the 67 cases in which 
urinary hydroxyproline and serum alkaline phosphatase were both measured 
in patients with cancer, 37 showed an increase in each and 18 an increase 
of urinary hydroxyproline in the face of normal alkaline phosphatase. In 
contrast Goombes et al. (1977) found 73% of their patients with overt 
metastases had raised hydroxyproline but that only Gtfo had increased 
alkaline phosphatase activities. Woodard (1953) suggested that the 
variability in alkaline phosphatase levels seen in these patients may 
be due to the fact that elevations of this enzyme could be an expression 
of a reactive reparative process secondary to bone destruction. 
Furthermore, Gribdff et al. (195*0 correlated the levels of serum 
alkaline phosphatase and calcium in patients in different phases of 
activity of metastatic bone disease. Their studies showed that the 
elevated alkaline phosphatase levels decreased prior to the onset of 
hypercalcaemia and that the fall in enzyme activity was an indication 
of impending acceleration of bone breakdown resulting in hypercalcaemia.
One more link between vitamin G and bone integrity may be in the 
calcification process. The short term effect of ascorbic acid on 
recently deposited calcium in chicks was discussed in Chapter 3 (see 
section 3.3). Further to this Humphreys and Zilva (1931) found that 
calcium and phosphorus retention by guinea pigs was lowered in scurvy
but only in the last stages, when the whole metabolism was affected.
Lanford (1939) claimed that orange juice added to the diet of rats 
caused increased calcium retention. Ruskin and Jonnard (1938) held that 
there was an intimate association between vitamin G and calcium, 
believing that calcium was absorbed from the intestine as calcium 
ascorbate. This compound they found to be adsorbed onto the blood proteins 
much more strongly than other salts of calcium. If, in fact calcium is 
absorbed from the intestine as ascorbate and if this ascorbate is more 
efficiently adsorbed onto the blood proteins than other salts of calcium, 
one might expect that by artificially increasing the amount of calcium 
ascorbate available it might be possible to secure a higher concentration 
of ionic calcium in the blood, which might stimulate the formation of 
bone in an injured area or aid repair processes following a wave of 
osteolytic activity. However, the hypothesis that vitamin G does play a 
role in calcification depends on the appropriate matrix being available 
to receive the mineral salts. Thus, it may be that vitamin G is only 
effective in influencing this and not calcium deposition itself.
Unfortunately, due to the small number of patients who showed metastatic 
development within the period of study it was not possible to conclude 
whether the long term ingestion of vitamin G was effective in increasing 
bone inte grity mediated through matrix or calcification changes and thus 
less liable to metastatic deposition. This question may be answered 
retrospectively as this group of patients continue to be studied.
5.2 Longitudinal Metabolic Profile of One Patient with Advanced Breast
Cancer
Longitudinal biochemical parameters for one patient (age 36 years) 
with primary breast cancer and subsequent skeletal secondaries are 
shown in Figs. 2Mr, 25 and 26. The clinical details and progress of this patient 
have been described in section 2.1.5 and Fig. 6. During the time of study 
the patient was undergoing chemotherapy (initiated after visit 1 and
Ltiuuuuy ic m m  \ jug ,u ueus / U  o
CN
CN
CD
LJ 00
o
.■Oo
LJ
CO
LJ
CO<
Li_
CO
CJ LJ M [Z CO
co ec 
CO h- 
CO LJ
CO pm
CD
O)
LL.
Q.
CO CN
Plasma A A  (mg 100 ml ^  a  ■.
f ...  - 1---i------------ 1------------27o  O  O  o
00 O CN
Urinary A A (mg 100 ml ) a— a
V
is
it 
N
um
be
r 
(m
on
th
ly
 
in
te
rv
al
s)
Fi
g.
 2
5 
LO
NG
IT
UD
IN
AL
 
Un
if
-J
Ai
iY
 
HY
Oi
iO
XY
P.
lO
LI
L'
E 
(O
ll
Pr
o)
 
CP
E 
AT 
I M
E 
(C
r)
 
PR
OF
IL
E 
OF
•   : »---
sO N" CN
6 0 6
OH Pro (m m ole  dm”3) 0---0
f-  :----:------ >— --------------- ■*
so ^  CN
OH Pro*. Cr a*..*a
Vi
si
t 
N
um
be
r 
(m
on
th
ly
 
in
te
rv
al
s)
CN•O00
00
CO
CL
CJ
Ld CQ CLLd
Ld
Ld • o»
Ld
Ld Ld
cr rr
CD 00
a
LO>*
Ld >o
o
l i ­
ft CO 
CD Ld 
'— ■ CO
Ld
Ld
CO
CD * CO
o'
o
* CM
GO
00 CN
CNCO CNCN-CN
Plasma Ca (m mole dm 3 ) ©—
o
o S'Qco
o
o
CN
O
o
A P  _( IU )
Vi
si
t 
N
um
be
r 
(m
on
th
ly
 
in
te
rv
al
s)
terminated after visit 5) and concomitantly ingesting 5g ascorbic acid 
daily. The last blood and urine samples were collected 2 months before 
the patient died.
Fig. 2k shows a progressive fall in leucocyte ascorbic acid concentrations
during the first two months of chemotherapy. Initially this appeared to
be due to its passage into the plasma. This, however, was transient
and both plasma and leucocyte pools appeared to be desaturated by visit
••I -83. Relative values at that time were 1.05mg 100ml and 22jig 10* cells 
for plasma and leucocyte ascorbic acid respectively. These are levels 
that would be expected in healthy individuals receiving a normal intake 
of the vitamin from the diet. These levels clearly do not reflect the.dose 
of 5g/day of ascorbic acid that this patient was taking. After visit 3 
there appeared to be a progressive increase in plasma and leucocyte 
ascorbic acid levels, the former reaching a peak saturated level of 
2.2mg lOOml”  ^following the cessation of chemotherapy, which again seems 
to be due to an influx from the short term leucocyte stores. This 
change was reflected by a fall in hydroxyproline/creatinine ratio 
(Fig. 23 ) which prior to chemotherapy was pathologically high (^ ,8 s l) 
and fell to a minimum value of 1.5 : 1 within 3 months and settled at a 
low stable value (2.1 : l) when the cytotoxic drugs were withdrawn. This 
low ratio was maintained for k months, which possibly could be due to the 
combined effect of the integrity of the bone brought about by ascorbic 
acid and to the antitumour action of the cytotoxic drugs. The separate 
determinations show the fall in hydroxyproline/creatinine ratio at visit k 
to be due to a large increase in creatinine excretion which remained 
relatively constant during the subsequent 'trough' period following 
chemotherapy, this, however, does not detract from the fact that 
hydroxyproline excretion per se appeared to respond to the therapeutic 
measures. Furthermore, the urinary hydroxyproline/creatinine values showed 
a return towards pathological levels as the condition of the patient
deteriorated. Neoplastic bone activity increased around March and June 
I98O.(Fig. 6). During these months the patient received local 
radiotherapy to both spine and pelvis, corresponding hydroxyproline/ 
creatinine ratios were high (approximately 3 • l) and the plasma and 
leucocyte ascorbic acid concentrations which had previously fluctuated
around the higher limits of the normal range began to decrease and fall
"»n —8
to 0.715mg 100ml" and 27.2jig 10" cells respectively. It would seem
that in this patient the urinary hydroxyproline/creatinine ratio 
reflected the progression of disease and its response to therapy and at 
times of increased metastatic activity high values of this ratio were 
reflected by relatively decreased ascorbic acid concentrations in the 
blood considering that the patient was ingesting large doses of the 
vitamin.
Blood levels of the vitamin did not appear to undergo any seasonal
variation. The lowest concentration of ascorbic acid in the leucocytes
—8occured in September (22/ig 10~ cells), the value increased in October
—8and November, fluctuated around 30pg 10" cells during the rest of the
—8winter, peaked in April and May (^ Ojug 10" cells) and fell to lower 
values in June before the patient was admitted to hospital. It would be 
expected that the ingestion of 5g of ascorbic acid per day would 
override any relatively minor changes in the intake of vitamin G 
containing foods which may occur during the year.
The early morning fasting concentrations of urinary ascorbic acid 
(Fig. 2*0 fluctuated greatly from month to month and seemed to alternate 
between periods of relative vitamin release and retention. The urinary 
ascorbic acid profile of this patient almost appeared graphically 
cyclic, however, the regular peaks and troughs failed to correspond to 
any treatment regimens employed.
The calcium profile of the patient (Fig. 26) reflected,,to a certain
extent, that observed in the hydroxyproline/creatinine ratio. The
unstable elevated plasma calcium levels seen initially (2.7mM), which
may have been a net result of previous hormone treatment, showed a
successive fall during chemotherapy. This remained low during subsequent
visits, and normal values were found even when neoplastic skeletal
activity was prevalent as indicated by a high hydroxyproline/creatinine
ratio and increased total alkaline phosphatase levels of 318 and 3^8 IU 8m
for visits 10 and 11 respectively. Unfortunately in this case it was not
possible to differentiate between alkaline phosphatase of bone and liver
origin using the standard electrophoretic techniques employed at St.
Luke's Hospital, Guildford and the possibility of increased plasma
r
alkaline phosphatase ocoloring as a result of liver metastases cannot be 
ruled out, especially considering the invasiveness and advanced state of 
the disease. The coexistence of normocalcaemic values with high alkaline 
phosphatse levels highlights the confusing nature of the interrelationships 
between various bone metabolites in the presence of known skeletal 
activity..
The excretion of calcium fluctuated from month to month in this 
patient. It is interesting to note that there was a rise in urinary 
calcium concentration at visit 9» prior to the patient undergoing 
radiotherapy to the spine.
Although the number of patients studied in this extensive fashion 
was small and therefore of interest mainly from an individual point of 
view there are several interesting salient points arising from the 
previous discussion.
Primarily, it has become obvious that the nine month observation 
period employed in this study was too short in order to examine possible 
metabolic changes which may herald the appearance of overt metastatic 
disease. There appeared to be considerable individual variation in all
parameters with the possible exception of urinary hydroxyproline/creatinine 
ratio, both before and after bone involvement. All but one patient showed 
consistent normal hydroxyproline excretion before skeletal disease yet 
afterwards, two out of the three patients revealed elevated ratios in the 
presence of variable values for other metabolites atudied.
The interrelationship between these measurements is confusing and 
complicated by the effects of various treatment regimens, differing 
dietary intakes and variable fundamental conditions of experimentation. 
Finally, as to whether the ingestion of ascorbic acid has affected 
skeletal metastasis is still questionable. However, this study will 
provide more information as these patients continue to be observed in years 
to come.
CHAPTER SIX
6. GENERAL DISCUSSION
6.1 Inter-relationship Between Tryptophan and Ascorbic Acid
The work described in this thesis was initiated to investigate the 
effects of a large (3g) daily dose of ascorbic acid on the progress of 
breast cancer, and in particular, its effects on the urinary excretion of 
hydroxyproline. As the study progressed it was decided to concurrently 
investigate certain aspects of tryptophan metabolism in the same patients. 
It seems possible now to suggest an inter-relationship of the findings in 
thas& two aspects of the study.
Patients with early breast cancer and with benign breast disease, 
when supplemented with vitamin C, absorbed large amounts of the vitamin. 
Thus, the plasma levels of ascorbic acid rose in both groups in the 
expected fashion in response to the large intake. Entry into the tissues 
was, however, delayed, as evidenced by the slow rise in their leucocyte 
levels. It is evidently not excreted in abnormally large amounts in the 
urine although there was considerable individual response. Further work 
clearly needs to be done to follow up these observations. The patients 
concurrently had low circulating levels of total tryptophan, although 
there was no difference between patients receiving the ascorbic acid and 
those that did not receive the supplement. It seems possible that iron 
metabolism may form a link between the metabolism of both ascorbic acid and 
tryptophan.
Wilson (1973) has thoroughly discussed the possible synergistic effect 
of iron and ascorbic acid. Specifically, the presence of ferrous iron 
also promotes the in vitro uptake of ascorbic acid by the leucocytes. 
Increasing concentrations of iron in the incubating fluid result in 
proportionate increases in the uptake of ascorbic acid by the leucocytes 
in an in vitro system (Loh and Wilson, I97O a). Evidence also suggests that 
ascorbic acid influences haemoglobin formation by its action on iron 
transfer mechanisms into and out of the liver (Cox, 1968). Tryptophan 
pyrrolase contains both copper and haem groups. It could be postulated that
the activity of this enzyme is modified by the fluctuation in circulating 
iron associated with the changes in ascorbic acid utilisation seen in 
malignancy. Tryptophan pyrrolase is the rate limiting enzyme in the 
catabolism of tryptophan. A number of hormones are known to influence the 
activity of this hepatic enzyme (§1.2.4). A more obvious link between the 
der -anged tryptophan metabolism and ascorbic acid utilisation seen in cancer 
patients could therefore be of hormonal origin.
Rose,(1967 a), for example, demonstrated the abnormal level of 
tryptophan excretion in cancer patients both before and after mastectomy 
so that the results reflect a general underlying hormonal disturbance 
rather than the presence of the tumour alone. Bell et al. (1971) found a 
pronounced difference in the relationship between excretion of steroid 
hormones and tryptophan metabolites between patients with breast cancer 
and normal controls. The cancer patients with low steroid ratios tended 
to have abnormally high excretory levels of tryptophan metabolites. The 
authors further reasoned that in these patients there would certainly be 
a higher level of total cortisol relative to the metabolites of the 
androgens, such as etiocholanolone. Furthermore, because there is decreased 
binding of cortisol by transcortin in breast cancer patients (Bell et al.,
1967), a higher proportion of the more active unbound cortisol will 
result. These changes in the level of steroid hormones could act ; 
synergistically in potentiating a higher tryptophan pyrrolase activity.
The higher level of cortisol will selectively stimulate the synthesis of 
the apoenzyme protein, whereas the reduced level of androgens will 
result in a decrease in general anabolic processes, with the direction 
of tryptophan into the catabolic pathway rather than into the general 
amino acid pool for protein synthesis. In addition to the contribution of 
androgens and corticosteroids to the general hormonal imbalance, Rose 
(1967 a) suggests that variations in the levels of oestrogens may also be 
pertinent.
The argument that tryptophan abnormalities are merely an expression of 
hormonal imbalances which may precede breast cancer could be extended 
to the ascorbic acid observations of this study.
Generally, there has been considerable discussion about differences 
between the sexes in their blood ascorbic acid values. Griffiths et al. 
(1967) found that women have higher concentrations than men. Loh and 
Wilson (1971 b) have demonstrated that sex differences disappear at the 
age of 60. A specific link appeared to exist between lutenizing hormone 
and ascorbic acid as indicated by the similarity in their excretory 
patterns which suggested that their metabolic paths are closely interlinked 
after ovulation (Loh and Wilson, 1971 d).
There is further evidence of ascorbic acid and hormonal interaction.
For instance, Lewin (1976) presents a lengthy argument concerning the 
function of ascorbic acid as an inhibitor of phosphodiesterase activity 
and thus maintaining cyclic AMP levels. Cyclic AMP appears to be the 
secondary messenger in the action of many hormones. In addition to this, 
ascorbic acid is postulated to aid in the oxidative formation of 
noradrenalin, the inactive precursor of adrenalin (Lewin, 1976).
It is well recognised that glucocorticoids can increase the platelet 
count in vivo in man. Numerous findings suggest that ascorbic acid is 
involved in the same way in the production and secretion of adrenal 
cortical hormones. The mechanism of action is not clear. Indeed, Kakar 
(1978) provides a scheme by which glucocorticoids and vitamin G have
-4
synergistic as well as antagonistic reactions. A further example of 
steroidal influences., was provided by Bartholomew (1972) who described 
clinical scurvy in a patient with rheumatoid arthritis treated with 
prednisone.
This could be the active aetiology of this study. Hormonal imbalances 
which are known to be associated with breast cancer patients (Bell et al.,
1971) could, have subtle influences on both ascorbic acid, and tryptophan 
metabolism which are manifested by increased demands for these metabolites 
(Fig. 27).
6.2 Conclusions
It is the opinion of this thesis that a higher intake of ascorbic 
acid is required prophylactically and more so therapeutically in early 
breast cancer patients not only to meet the inferred concentrating effect 
of the tumour but also to counteract the increased requirement due to 
stress and anorexia which are reported to be associated with the disease? 
itself. The feasibility of such a supplementation is increased by the 
good toleration shown by this set of patients both to short term (3g) 
loading doses and long term (3g/day) ingestion of vitamin C.
From the small number of results from early breast cancer patients 
showing subsequent metastatic disease it appears that urinary 
hydroxyproline/creatinine determinations could be valuable as an early 
indicator of metastasis to the skeleton if repeated consistently at 3 
monthly intervals following mastectomy. The routine determination of 
hydroxyproline excretion in relation to creatinine merits further long 
term investigation. Vitamin C ingestion did not appear to have any long 
term effect on urinary hydroxyproline/creatinine ratio in either early 
breast cancer or metastatic patients.
Random calcium and phosphor us determinations appear to have little 
value as either an early indicator of skeletal metastasis or as an 
indication of the progression of established osseous deposits. The 
lability of these minerals necessitates intensive balance studies, 
involving consistent observation, to be of any use in this field.
The tryptophan metabolism in early breast cancer patients merits 
further investigation. It is important to explore the significance of the 
shift in equilibrium of tryptophan catabolism towards niacin synthesis
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in this set of patients. The diagnostic implications of the consistently 
depleted levels of plasma total tryptophan seen in the breast cancer 
patients at such an early stage of the disease should be examined further. 
Hormonal influences have been hypothesised to be of underlying aetiology 
in both ascorbic acid and tryptophan abnormalites observed. If in the 
latter case this is correct and ,these hormonal imbalances actually do 
precede^  clinical manifestation of disease this may provide a useful 
screening test to identify those at risk.
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APPENDICES
APPENDIX 1
Individual Values of Plasma Ascorbic Acid (mg 100 ml~^) for Early
Breast Cancer Patients
1-----  VISIT NO
INITIAL 1 2 3 4 5 '
UNSUPPLEMENTED
M.K. 023' 0.19 0. 62 0.30 1. 00
J C 0.07 0.55 0.48 0.33 -
E.G. 1.34 0.64 1.10 DIED ■ —
M.S. 1.31 1.4l 1.06 0.58 0.69
M.A. 4.22 1.37 1.43 1.31 0.79
E.R. 0.74 0.51 0.47 1.46 0.76
P.H. 0.39 0.64 0.08 0.66 0.18
N.S. 0.39 0.61 0.75 0.88 2.90
E.W. 0.06 1.26 0.72 1.19 -
M.T. - 0.68 0.85 0.96 1.07
R.R. 1.21 - 0.73 1.36 1.15
A.C. 1.22 0.97 1.23 1.56 0.91
E.T. 1.49 1.12 1.32 1.69 0.90
M.J. 0.92 1.31 0.98 - 1.28
M.N. 1.85 0.82 0.83 1.15 0.87
J.W. 0,35 1.09 0.44 1.90 1.09
I.B. 1.76 1.72 - 1.42 1.52
J.H. 1.88 0.46 0.54 1.19 -
F.B. 0.70 0.09 O.91 1.63 1.53
K.H. 0.61 1.58 1.01 - 0.81
J.H. 0.88 0.67 0.51 - 0.81
A.G. 0.08 0.28 o.37 0.27 0.31
I.D. 2.59 - 0.65 0.48 0.58
L.W. 0.34 0.32 0.i}4 0.26 0.07
A.W. 0.77 0.76 1.19 1.58 0.74
VISIT NO
INITIAL 1 2'- < 3 4 5
SUPPLEMENTED (3g/day)
E.H. 0.31 0,85 ’ r - -
M.W. 0.28 2.14 1.82 1.88 2.04
A.P. 1.18 0.95 O.56 1.37 1.29
B.C. 1.43 2.13 1.28 1.68 1.81
D.T. 0.64 2.82 1.77 2.27 2.73
D.S. 0.83 2,52 1.50 2.50 4.15
E.H. 0.06 1.51 1.03 2.01 2.90
P.R. 0.26 1.68 0.55 4.20 1.17
N.A. O.5I 1.95 O.85 1.20 1.70
G.T. 0.64 2.13 2.00 I.89 2.45
M.C. 1.03 1.48 O.96 0.92 1.94
K.R. 0.75 - - - -
K.T. 0.81 1.33 1.65 1.66 3.61
M.G. 1.61 1.66 0.44 1.66 2.51
F.P. 0.61 2.29 1.36 1.89 2.34
E.M. 0.36 0.62 1.08 2.61 -
R.S. 0.91 0.59 1.97 1.60 1.69
A.W. 0.14 1.60 1.56 2.21 -
F.S. 0.47 2.09 1.48 2.42 -
R.S. 1.11 3.14 3.20 2.69 0.59
M.M. 0.71 0.94 2.77 2.37 3.55
M.P.M. 1.94 0.64 2.54 1.45 2.00
M.B. 1.94 2.5? - 1.52 3.02
B.M. 0.3.0* 0.21 O.13 0.51 1.27
L.A. 1.15 2.27 - 2.65 1.00
W.F. 1.01 2.27 - 1.96 -
B.E. O.69 - - - -
APPENDIX 2
o
Individual Values for Leucocyte Ascorbic Acid (jig 10 cells) for 
Early Breast Cancer Patients
1 .VISIT NO "..... ( 1— VISIT NO " ' 1
INITIAL 1 2 3 4 5 INITIAL 1 2 3 4 5
UNSUPPLEMENTED SUPPLEMENTED (3g/day)
M.K. 23.19 21.93 22.86 15.78 22.85 E.H 33.07 15.74 - — -
J.C. 29.02 38.46 14.23 16.19 - M.W. 17.26 15.07 19.55 33.99 34.50
E.G. 49.62 26.76 14.87 DIED — A.P. 30.27 38.46 22.48 23.75 10.80
M.S. 20.64 13.67 22.13 12.02 8.27 B.C. 32.98 27.30 8.83 26.33 21.90
M.A. 36.08 10.57 46.47 36.46 14.90 D.T. 26.21 28.65 39-99 37.51 34.30
E.R. 49.24 69.62 10.28 27.03 22.70 D.S. 34.40 24.55 27.14 27.00 29.03
P.H. 24.66 22.06 8.72 14.99 7.30 E.H. 10.88 15.18 34.90 34.95 36.30
N.S. 17.56 10.15 16.55 18.55 21.10 P.R. 29.91 36.67 19.94 23.65 21.37
E.W. 7.45 13.38 17.62 18.22 10.10 N.A. 6.72 29.ll 22.79 27.56
M.T. - 13.90 22.78 12.34 - G.T. 9.51 28.73 26.54 20.17 18.16
R.R. 9.21 10.00 16.21 20.79 14.38 M.C. 11.82 24.38 24.34 26.89 42.82
A. C. 9.98 19.16 45.84 39.43 13.29 K.R. 27.41 - - - -
E.T. 29.13 47.94 43.94 26.20 17.72 K.T. 13.38 48.02 29.55 21.37 28.74
M.J. 40.32 20.82 19.33 14.00 25.06 M.G. 19.00 28.68 25.62 32.47 20.08
M.N. 19.01 14.06 20.78 32.36 13.39 F.P. 21.86 45*64 23.51 22.59 21.87
J.W. 12.63 36.78 17.52 17.60 24.02 E.M. 15.01 66.98 23.15 15.94 -
I.B. 29.69 17.90 19.82 21.92 21.05 R.S. 13.94 24.35 59.16 20.43 13.12
J.H. 20.17 20.95 22.57 30.28 - A.W. 26.51 45.18 24.20 27.03 36.12
F.B. 13.13 7.33 16.45 32.89 26.79 F.S. 28.86 17.37 16.05 21.68 4.12
K.H. - 31.81 - 3.24 24.30 R.S. 19.76 40.28 12.14 22.55 -
J.H. 30.43 24.76 31.88 28.77 41.56 M.M. 24.70 21.98 16.06 18.38 32.89
A.G. 3.56 25.51 19.54 13.68 16.96 M.P.M 8.52 4.21 25.84 22.83 30.50
I.D. - - 23.28 21.76 20.60 M.B. 17.16 - - 15.32 42.69
L.W. - 13.08 31.31 22.45 11.76 B.M. 20.05 35.43 31.30 19.72 40.13
A.W. 38.66 - 32.80 22.78 23.86 L.A. 12.33 26.88 - 19.55 13.50
W.F. - 33.66 - 17.08
B.E. 28.00 — — _ _
APPENDIX 3
Individual Values of Urinary Hydroxyproline/Creatinine Ratio for
Early Breast Cancer Patients
VISIT NO
INITIAL 1 2 3 4 5
UNSUPPLEMENTED
A.W. 2.4*1 2.1:1 2.7 1 1.4:1 2.0:1
M.K. 0.6:1 1.1:1 0.8 1 1.4:1 0.9:1
N.S. 1.8:1 1.5:1 1.3 1 1.2:1 1.6:1
E.W. 1.3*1 1.4:1 1.2 1 - 1.8:1
E.G. 0.6:1 0.6:1 0.7 1 DIED -
R.R. 1.0:1 1.4:1 1.9 1 2.1:1 -
E.T. 1.5:1 1.9:1 1.4 1 1.6:1 2.7:1
M.S. 0.8:1 0.9:1 1.0 1 1.5:1 0.8:1
M.A. 1.3*1 - 1.2 1 0.7:1 1.8:1
M.J. 1.0:1 0.9:1 0.8 1 1.4:1 1.6:1
P.H. 1.0:1 1.3:1 1.1 1 1.1:1 DIED
E.R. 1.3*1 0.9:1 0.9 1 0.9:1 1.4:1
J.C. 1.3*1 - 0.6 1 CHEMOTHERAPY
A.P. 1.0:1 - 0.8 1 1.0:1 0.3:1
M.T. 1.6:1 1.5:1 2.0 1 2.0:1 (CT)
A.C. 1.0:1 1.0:1 1.9 1 1.8:1 1.6:1
M.N. 1.2:1 0.9:1 1.3 1 0.9:1 1.5*1
J.W. - 0.8:1 0.6 1 0.6:1 -
I.B. 1.2:1 1.3:1 1.8 1 3.2:1 1.2:1
J.H. 1.3:1 1.1:1 1.7 1 2.1:1 -
F.B. 1.5:1 1.4:1 1.1 1 1.8:1 0.7:1
K.H. 0.8:1 1.0:1 1.8 1 3.9:1 1.1:1
J.H. 2.6:1 1.7:1 2.4 1 3.1:1 2.7:1
A.G. 1.2:1 1.4:1 1.1 1 1.5:1 -
I.D. 1.6:1 2.5:1 1.1 1 1.5:1 -
L.W. 2.1:1 1.8:1 1.4 1 - -
VISIT NO
INITIAL 1 2 3 4 5
SUPPLEMENTED (3g/day)
D.S. 0.3:1 2;0 1 1.3:1 1.3:1 2.8:1
P.R. - 1.5 1 2.3:1 1.7:1 1.4:1
E.H. 1.1:1 0.5 1 1.0:1 0.6:1 0.9:1
M.W. 1.2:1 1.4 1 1.3:1 1.3:1 1.7:1
N.A. 11.1:1 1.6 1 1.0:1 1.5:1 0.9:1
G.T. 0.8:1 0.8 1 0.7:1 1.1:1 1.4:1
K.T. 0.6:1 0.7 1 0.7:1 0.8:1 0.8:1
F.P. 1.4:1 1.8 1 0.6:1 1.2:1 1.8:1
B.C. 2.3:1 2.3 1 1.3:1 1.6:1 3.4:1
R.S. 1.1:1 2.0 1 1.4:1 1.3:1 2.0:1
M.C. 1.7:1 1.0 1 0.1:1 1.3:1 1.1:1
M.G. 1.7:1 2.8 1 2.1:1 2.2:1 1.9:1
M.H. 1.3:1 1.4 1 - - -
D.T. 1.9:1 1.3 1 1.5:1 1.7:1 1.2:1
E.M. 1.1:1 2.0 1 0.9:1 1.5:1 1.9:1
A.W. 1.4:1 1.2 1 1.8:1 1.9:1 1.5:1
F.S. 1.1:1 0.8 1 1.4:1 1.1:1 1.5:1
R.S. 1.2:1 0.5 1 0.9:1 0.7:1 1.3:1
M.M. 1.2:1 1.6 1 1.0:1 3.8:1 1.8:1
M.P.M. 1.4:1 1.4 1 1.4:1 2.5:1 1.2:1
L.A. 0.1:1 1.8 1 2.2:1 3.6:1 1.5:1
M.B. 2.1:1 2.2 1 4.1:1 3.6:1 2.6:1
B.M. 1.6:1 2.5 1 2.4:1 0.6:1 -
W.F. 6.5:1 8.1 1 - - -
B.E. — — - _ —
APPENDIX 4
Individual Values of Urinary Creatinine (mmoles dm~^) for Early
Breast Cancer Patients
VISIT NO
INITIAL 1 2 3 4 5
UNSUPPLEMENTED
A.W. 9.0 10.2 7.9 13.0 5.0
M.K. 14.4 11.0 9.3 10.6 8.8
N.S. 3.3 7.2 4.6 6.4 5*6
E.W. 4.0 5.3 4.2 - 3.3
E.G. 3.6 5.1 - DIED -
R.R. 4.1 5.0 6.4 5.8 -
E.T. 4.6 7.2 4.3 12.2 5.9
M.S. 7.4 8.6 8.4 4.6 9.5
M.A. 6.6 4.8 8.6 9.0 8.2
M.J. 8.8 10.0 13.0 7.2 2.0
P.H. 4.1 8.0 7.6 4.6 DIED
E.R. 4.0 10.0 4.4 9.5 3.6
J.C. 17.4 - 27.6 - «.
A.P. 4.8 3.2 6.4 4.8 4.0
M.T. 6.2 5.3 7.5 7.5 -
A.C. 4.0 4.6 4.3 3.4 7.4
M.N. 5.8 4.6 10.0 5.6 5.4
J.W. 3.4 6.0 5.0 9.9 -
I.B. 9.8 5.3 4.9 5.7 9.8
J.H. 9.8 9.7 6.6 8.0 -
F.B. 6.6 9.6 13.0 7.2 15.6
K.H. 2.4 6.8 13.0 2.0 9.2
J.H. 5.4 3.6 4.6 4.6 2.2
A.G. 5-9 7.6 2.6 4.0 3.9
I.D. 11.7 8.5 14.7 10.4 -
L.W. 6.1 5.2 8.0 -
VISIT NO
INITIAL 1 2 3 4 5
SUPPLEMENTED (3g/day)
D.S. 10.4 3.9 11.6 13.0 5.0
P.R. 11.1 7.8 9.2 8.0 9.6
E.H. 22.4 12.6 9.4 15.2 13.6
M.W. 12.6 6.5 6.5 9.0 10.2
N.A. 6.0 4.5 - 6.5 7.8
G.T. 4.8 4.0 1.4 5.4 3.7
K.T. 3.2 - 5*6 4.8 2.4
F.P. - 3.3 8.8 3.3 3.8
B.C. 4.4 3.1 8.6 8.4 7.0
R.S. 12.3 3.0 7.4 7.0 4.0
M.C. 3.9 4.1 8.3 3.0 4.8
M.G. 4.1 2.8 3.4 3.6 5.4
M.H. 6.4 2,8 - -
D.T. 9.2 6.1 7.2 6.0 7.8
E.M. 6.1 4.0 7.4 4.8 3.1
A.W. 5.6 - 8.0 6.4 2.7
F.S. 5.4 4.8 2.2 7.6 5.5
R.S. 7.4 7.2 4.7 9.9 3.8
M.M. 9.3 5.0 5.0 4.7 5.0
M.P.M. 4.9 5.8 4.2 5.3 3.8
L.A. 8.2 7.8 3.2 4.3 8.4
M.B. 5.1 4.4 3.4 5.0 9.1
B.M. 5.0 1.6 6.9 5.4 -
W.F. 2.3 3.8 6.1 - -
APPENDIX 5
—3Individual Values of Urinary Creatinine (mmoles dm J) for Benign 
Controls. All patients received 3g Ascorbic Acid Daily
I—  VISIT
PATIENT INITIAL 1 , 2
P.G. 4.5 -
G.F. 15.8 15.5
P.M. 4.2 5.0
E.D. 3.3 5.8
B.S. 8.4 10.0
F.A. 5.2 1.6
W.S. 10.0 8.4
B.B. 14.5 13.2
M.G. 2.0 2.1
J.A. 3.2 1.7
